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Abstract 
In recent years, the exploitation of phenomena surrounding microfluidics has seen an increase in 
popularity, as researchers have found a way to use their unique properties to create superior 
design alternatives.  One such application is representing the properties and functions of different 
organs on a microscale chip for the purpose of drug testing or tissue engineering.  With the 
introduction of “organ-on-a-chip” systems, researchers have proposed various methods on 
various organ-on-a-chip systems to mimic their in vivo counterparts.  In this review paper, a 
systematic approach was taken to review current technologies pertaining to organ-on-a-chip 
systems. Design processes with attention to the particular instruments, cells, and materials used 
were reviewed and presented.  
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1.  Introduction 
Before a new drug is released in the market it must go through intensive testing; prior to 
approval for human testing, most drugs first need to be tested for safety through animal testing. 
The use of animals in such experiments is often expensive, time consuming, ethically 
controversial, and is often an inaccurate representation of actual human response [1]. Two-
dimensional cell culture models are also not the best solution because the cells do not respond 
the same way when their surrounding environment is drastically different from that of a human 
body [2]. Organ-on-a-chip technology provides a practical solution to many of the issues 
presented by both two-dimensional models and animal testing. An organ-on-a-chip is a cell 
culture model with microfluidic channels [3] configured such that it is capable of simulating the 
activities and physiological responses of an entire organ [4]. This type of device creates a 
uniquely accurate method for replicating the organ structure of human tissue and observing the 
biological responses, as opposed to predictions based on extrapolated data from animal testing. 
The chip is portable, requires little amounts of materials, creates a small footprint, and is cost 
effective, making its applications limitless [5].  With some more improvements and careful 
testing, this technology may be able to help drugs get into the market faster, increase the number 
of new drugs investigated, and possibly eliminate animal testing altogether. 
 Many ‘organ-on-a-chip’ devices have already been made [6]. For example, the Wyss 
Institute at Harvard have fabricated a ‘lung-on-a-chip’, which is mainly made of three 
microfluidic channels, with the center one holding a porous membrane on which alveolar 
epithelial and vascular cells are grown [7]. A breast-on-a-chip has also been developed to study 
tumor nanoparticles for identifying and treating tumor cells [8]. 
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The next step for this technology is to connect various organ-on-a-chip devices to one 
another to create a “body-on-a-chip.” This configuration could possibly allow researchers to 
investigate the effects of substances not only on the individual organs but to replicate the 
interactions between each component, providing a more comprehensive analysis which could 
ultimately revolutionize how drugs are developed. 
 
2. Microfluidic Organ Types and Functions 
2.1 Liver 
The approval of introducing new drugs to the market has proven to be a difficult barrier to 
overcome due to the risks associated with them. As the cost of bringing a new drug into the 
market keeps rising in the United States, there becomes a larger need to have high performance 
pre-clinical drug screenings using in vitro models. The liver has proven to be one of the most 
difficult organs for drug approval, due to the strong interactions it has with other organs, as well 
as its sensitivity to the metabolism of certain drugs [9].  This leads to a high percentage that are 
discontinued and removed from the market. Technologies to study microvascular structure and 
functions have remained largely unchanged since the late 1970’s. Improving the systems and 
technology used to test for toxicity is key to providing better predictions of toxicity and ensuring 
the safety and efficacy of new drugs well before they reach market [10]. There has been a 
considerable amount of research done in the area of toxicity testing on organs, with hopes to 
fabricate a simpler, efficient, effective, and accurate microfluidic system mimicking the 
functions of the liver. 
Cells used to represent the liver primarily consist of hepatocyte cells, due to their 
uncanny ability to mimic liver functions [11].  Research has taken advantage of this trait in order 
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to produce a working liver-on-a-chip design [12]. Toh et al. [13] created a system that can also 
address the cell culture chamber independently, so that different drugs concentrations can be 
simultaneously increased. The 3D microfluidic cell culture system, dubbed the “3D HepaTox 
Chip,” is designed to support 8 parallel channels containing separate cell cultures, with a linear 
concentration generator to provide different levels of drug concentration to each channel. An 
array of micropillars (30 µm x 50 µm) separate the cell culture channel into three compartments 
consisting of a 200 µm wide central culture with two side compartments.  The central culture had 
the purpose of keeping a constant cell suspension, while the side compartments introduced flow 
from the output of the concentration generator. To assess the functionality of the cell culture, 
albumin production and various metabolic activities were measured. Results showed that this 
microfluidic model was equally capable of the functional maintenance of the hepatocytes as a 
multi-well plate model, if not more so.  The hepatotoxicity testing was performed using five 
model drugs: acetaminophen (20mM), diclofenac (1000µM), quinidine (1000µM), rifampin 
(2000µM) and ketoconazole (420µM). Results showed that the cells were more sensitive to the 
drug-mediated hepatotoxicity than the multi-well plate cultures. The toxicity data also showed a 
positive correlation with comparable in vivo toxicity data.  
While some researchers focus on using 3D microfluidic devices for toxicity testing, 
others have focused on functionality.  Nakao et al. [14] developed a microfluidic cell culture 
device that mimics the microscopic structure of the hepatic cords. Due to the decline in liver 
specific functions caused by freshly isolated hepatocytes rapidly losing their membrane polarity, 
a new technique for maintaining the cells was proposed, in which hepatic activity was prolonged 
by suctioning the cells into the cord-like compartment of the device, creating a “collagen 
sandwich culture”. The design is such that the tip of this compartment has an asymmetrical tip 
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that can house two cells side-by-side. Current liver tissue cultures do not a have separate 
compartment to collect secreted bile and are accumulated in the cultured cells. However, in vivo, 
the bile is excreted into the bile canaliculi and is then discharged into bile ducts. The area of 
culture was formed by aligning two lines of hepatocyte cells in a similar way to the hepatic 
cords. The aligned hepatocytes were able to self-organize themselves and form bile canaliculi 
along the hepatic cord-like structure. The device has a medium flow channel that is 100µm wide 
and 30µm high, a cell loading channel that is 200µm wide and 30µm high, a cell culture area that 
is 37µm wide and 30µm high and an endothelial-like barrier. Additionally, there are 30µm long 
narrow slits with 10µm intervals that allow the nutrition to go into the cell culture area. The 
fluorescent substrates accumulated in the cells were aligned and formed a bile canaliculi with 
tight junctions. This bile canaliculi showed the ability to utilize nutrients in the culture medium 
stream. Additionally, using the MRP2 and CD147 marker proteins, the transportation properties 
of the system were tested, and the markers were found to be distributed in a similar fashion as 
they would in an in vivo counterparts. 
Incorporation of biosensors has also been studied as a means to create improved analysis 
of a system, in addition to the development of the microfluidic platform. As part of the 
construction done by Schober et al. [15], AlGaN/GaN nanosensors were integrated into their 
microdevices, and were used for optical monitoring of the cells. The design consists of a base 
and top module used for the purpose of carrying the cell culturing substrate; within this contains 
a microfluidic pumping system used for circulation and perfusion.  The cultivated cells are 
contained in a polymer scaffold system, called “MatriGrid.” The hepatoma cell line, HepG2, 
demonstrated the biological application of the microreactor. Analysis was done for 2D cell 
culture, 3D culture without perfusion, and 3D culture with perfusion. Tests for viability were 
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completed and analyzed for the cells cultured in the 2D and 3D systems over a course of 19 days. 
All three cultures showed a similar general relationship between the G1,0, D, and G2,m phases, 
with the 2D culture displaying a higher proliferation rate than what is typically seen in vivo.  The 
notable difference came from monitoring the albumin secretion of the cultures. Albumin 
secretion was used as a metabolic marker to observe the similarities between the cultures used 
during the experiment and the in vivo counterpart.  Results showed that only the 3D culture 
without perfusion strayed from predicted results, showing a notable increase in production over 
time.  Additionally, the system with and without HepG2 cells went through pH testing.  The 
results showed a steading increase in pH for the system with HepG2 cells, and a relatively 
unchanged pH for the system without.  This is due to the conversion of glucose to lactate that 
occurs in vivo as well. These results showed a strong signal with little noise,showing reliability 
that can be applied for long-term monitoring of cells. Their perfused bioreactor system mimics 
some of the features that are found in vivo as well. 
Lee et al. [16] designed a microfluidic device that contained polyethyleneglycol (PEG) 
pillars within a weaving channel, with each pillar containing rat liver microsomes enclosed 
within a 3D hydrogel matrix.  The pillars took up around 35% of the space within the channel 
and were roughly spaced 100µm from each other. Gravity induced flow was able to mimic the 
metabolism reaction and the transport system of the liver. The concentrations of seven different 
substrates were used to test the P450 reaction in a microsome solution within a standard well 
plate system, ranging from 2µM to 80µM. Two trials were conducted: one in which the 
microsomes were in the solution phase by themselves and another in which the microsomes were 
enclosed within the 3D matrix.  Data was extrapolated and a mathematical model of the system 
based on Michaelis-Menten kinetics was produced, showing a high level of agreement between 
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the two. The chip was then analyzed and a model was created.  This model also showed a high 
level of agreement. However, ideal assumptions were created to simplify the model, including: 
no variation in the z-axis, completely effective diffusive properties within the channels, a 
completely homogeneous environment (a single diffusion coefficient), and a uniform reaction 
space within the channel. Certain steps still need to be taken to improve the model, like 
improving the diffusive properties and convective flow rate of the device, but the success of the 
model shows that the metabolic properties within a microfluidic liver model can be mapped and 
understood to create an experimental equivalent for use in liver-on-a-chip applications.  
While the use of a single cell culture has shown to yield successful results, using multiple 
cells in a liver-on-a-chip model has the potential for even more realistic in vitro results due to the 
livers true complex nature being composed of multiple cells in interaction with each other. This 
line of research has produced notable results as well [17].  Schütte et al. [18] used this approach, in 
addition to developing a microfluidic test system for liver toxicity. This system is an organ-like 
liver 3D co-culture of hepatocytes and endothelial cells. The chip allows for the assembly of 
primary human hepatocytes and endothelial cells in a sinusoidal-like manner with the use of 
dielectrophoresis (DEP). The system was integrated with microfluidic channels that allowed for 
continuous perfusion of the culture medium and compound testing. The features within the 
channel structure are comprised of electrodes at the outer chamber walls with a variation of the 
channel cross-section in between. Micro pillars were attached to the front and back ends of the 
gaps to represent flow barriers, which reduced the flow velocity and shear forces. The device 
was connected to a pump system for fluid control with AC voltages of up to 300 Vpp. Each 
design had a gap region 100μm high, 100μm wide, and 1,500μm long, as well as a 33º angle of 
inclination on the bottom channel so that particles traveling along the bottom can still be lifted 
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into the gaps by dielectrophoretic force (Fig. 1a). The device only trapped the healthy living 
cells, thereby resolving a problem of the past. Once the electric field was turned off, the cells 
showed a more even distribution, with the hepatocyte cells in the center and the endothelial cells 
outside of them (Fig. 1b).  This distribution was sufficient enough to not be affected by the flow. 
 
Fig. 1. Cross section of the microchannel displaying the general layout.  Two electrodes are positioned at 
each wall of the channel, a) providing a dielectrophoretic force to the hepatocytes and the endothelial 
cells traveling along with the flow once voltage is applied to the system, with the design of the device such 
that the particles are maintained in the center.  b) Once the voltage is shut off, the particles are arranged 
such that the endothelial cells are positioned outside of the hepatocytes, while still being somewhat 
maintained in the center of the channel [18]. 
 
Another multi-cell design was created by Wagner et al. [19], who designed a multi-organ 
chip (MOC) platform that combined a microfluidic channel system with multiple separate tissue 
culture compartments. Liver micro tissues (HepaRG and HHSteC), as well as skin biopsies, were 
 
 
8 
combined and had successful long-term performance. The device contained microchannels and 
micropumps, as well as culture compartments for Transwell® inserts. The system allowed 
crosstalk between the two tissues, and was observed for 14 days while exposed to fluid flow. 
Consistent disk-shaped liver cells were formed during 2 days of having been cultured on the 
chip. The microchip device was able to culture two cell types while directly exposed to fluid 
flow, as well as maintain a metabolic steady state. It is able to culture and maintain cells over 
longer periods of time with the Transwell® inserts as the system showed it could be maintained 
for 28 days. 
 Additionally, multiple toxins can be used as well to increase the scope of the experiment.  
Shintu et al. [20] developed a microfluidic system with H NMR-based metabolomic foot printing. 
They used a small-molecule screening approach to characterize the toxicity in several 
compounds: ammonia (NH3), dimethylsulfoxide (DMSO), and acetaminophen (APAP). 
Hepatocellular carcinoma cells (HepG2/C3A) were used to model the liver, Madin-Darby canine 
kidney (MDCK) tubular epithelial cells to model the kidney, and a combination of both 
(HepG2/C3A-MDCK) as cell co-cultures. When the biochips are perfused, the supply of 
nutrients is restored, the cells proliferate, and a higher glucose and glutamine consumption is 
seen. HepG2/C3A is correlated with higher glucose concentrations and lower lactate and alanine 
concentrations when compared to the MDCK kidney. Additionally, the co-culture showed 
unique metabolite concentrations not expressed in any of the single cultures.  This information 
was used to control these differences to ensure that they have the same “starting point” with 
relation to their reaction with the compounds. A data-scaling method known as “SMART-scale 
analysis” was used to account for these differences.  Using this method, the relative increase and 
decrease of metabolic markers was analyzed. These fluctuations, both alone and in combination 
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with one another, can create results in various biological processes, including toxicity 
production.  An “integrated knowledge network” was created to map out these biological 
processes and their implications.  From this, the actions from the metabolic markers can be 
observed for toxicity screening purposes.  Experimental results were conducted and the 
metabolic responses were observed and compared alongside the theoretical data.  The results 
showed a high degree of compatibility for all three compounds. 
Integrating tissue slices is another technique used by researchers to create an in vitro co-
culture model [21].   Van Midwoud et al. [22] investigated whether intestinal tissue slices could 
also be cultured in a micro biochip with liver slices and also to see if their metabolic activity in 
incubation is better than in the well plate system. The intestine, as well as the liver, is important 
for the metabolism of xenobiotics. The liver and intestinal slices were obtained from male Wistar 
rats. They exposed the substrates to several mediums: 7-ethoxycoumarin (7-EC), 7-
hydroxycoumarin (7-HC) and lidocaine (Li), to see if their metabolic rates in the biochip were 
similar. The slices were also exposed to a primary bile acid, chenodeoxycholic acid (CDCA), to 
see the interplay between the two organs. One slice of liver and one slice of intestine were placed 
into a compartment culture perfusion system with a continuous flow of the mentioned mediums. 
The microdevice itself had 10 layers of polydimethylsiloxane (PDMS), which each had a 
thickness of 250µm and along with 6 microchambers. The device had a medium top/bottom inlet 
channel that was 500µm x 100µm, and a polycarbonate filter that had 8µm size pores and 10µm 
in thickness integrated at the entrance of the tissue chamber. The filter was 4mm x 2mm and held 
25µL. It was found that it is possible to successfully maintain intestinal slices in the same 
biochip with viability and functionality for at least 3 hours. With this system they were able to 
easily control the flow of the medium and transfer it from one organ to another. It was also 
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possible to link one microchamber to another for the use of perfusion and metabolic activity. 
They were able to integrate the liver and intestine, and it could potentially work for lung, kidney, 
and colon slices. 
Just like van Midwoud et al., Bricks et al. [23] developed a model to mimic the 
interactions between the intestine and liver. However, instead of using actual slices of the organs, 
they used the human carcinogenic epithelial cell line Caco-2 TC7, which is the clone of Caco-2 
cells, for the intestine, and hepatocarcinoma HepG2/C3A cells for the liver. A new microfluidic 
device called the Integrated Insert in a Dynamic Microfluidic Platform, or IIDMP, was used to 
evaluate the organ-organ interactions of the liver and intestine. This design consisted of 3 
perfusion units, each unit containing two wells used as reservoirs, one cell culture insert, and one 
microfluidic chip that was made of PDMS. The insert was contained within the first well, with 
circulation traveling through the bottom of the first well into the second well, by means of a 
microfluidic chip bridging the two wells.  A pump was used to bring flow from the second well 
back into the first well, thereby completing the cycle. The Caco-2 TC7 cells were cultured in the 
insert, while the HepG2/C3A cells were cultured in the microfluidic chip.  Both cells were 
individually tested for integrity and functionality before integration into the system.  Confluence 
of Caco-2 TC7 cells were found using transepithelial electrical resistance (TEER) measurements 
and permeability properties were found by monitoring Lucifer yellow transportation. Results 
showed high levels of both after sufficient time within static culture, suggesting that the system 
gained tight junction properties, which is in agreement with expected results.  Dynamic 
conditions proved to produce similar results.  HepG2/C3A cells were cultivated and the 
functional properties were tested in both dynamic and static conditions.  Dynamic conditions 
were tested with and without the influence of Caco-2 TC7 cells in the system.  Albumin 
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production was reported to be non-existent in the static culture, while producing higher values 
with the influence of Caco-2 TC7 cells compared to the system without them, despite the fact 
that the Caco-2 TC7 cells showed no production of albumin themselves.  Bricks et al. proposed 
that this was due to a stimulating effect that the Caco-2 TC7 cells have on the HepG2/C3A cells.  
The xenobiotic metabolism was tested using the EROD test.  The enzyme CYP1A was chosen 
for monitoring.  Results showed low levels of activity when compared to primary hepatocytes, 
with dynamic trials showing no metabolism after 24 hours and static trials showing no activity at 
all after 24 hours.  The co-culture of Caco-2 TC7 cells and HepG2/C3A cells were then tested by 
monitoring the CYP1A activity when the drug phenacetin was introduced to the system.  Both 
static (Petri) and dynamic (IIDMP) were evaluated.  The resulting APAP production was 
observed to be higher in the dynamic culture, despite the fact that the hydrophobic properties of 
phenacetin may have led some of it to be absorbed into the PDMS components of the IIDMP.  
When dynamic conditions with and without Caco-2 TC7 were tested, the system with Caco-2 
TC7 once again produced greater amounts of production.  This experiment reaffirms the 
hypothesis that integration of tissues from multiple organs creates a more realistic in vitro model 
due to both the simple connections and the underlying influences they have on each other. 
 
2.2 Lung 
In response to the lack of experimental model systems available that can accurately replicate 
human lung response and function, many are currently researching and developing new 
technologies. The microdevice, lung-on-a-chip, recapitulates the physiological and mechanical 
microenvironment of a living lung. This technology allows for the study of complex physiology 
of the human lung. With the aid of organ-on-a-chip technology, new drug therapies can be 
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developed, respiratory assist devices can be utilized, and pulmonary diseases can be 
characterized [24]. 
In early work by Huh et al. [25], a microdevice was developed which allowed for the 
analysis of the effects of liquid plug flows on human small airway epithelial cells (SAEC). The 
device consisted of two PDMS layers containing a microfluidic channel separated by a 
nanoporous membrane, modeled after the human airway epithelium.  Additional inlets and 
channels were created to connect a liquid plug flow generator.  Liquid plug flows were created 
using a device that would switch the air-liquid interface within the chip, as shown in Fig. 2. 
Through this device, the effects of an air intake model (useful for representing a healthy lung), 
fluid intake model (useful for representing the developing lung of a fetus), and a variable length 
two-phase plug flow model (useful for representing respiratory diseases such as pulmonary 
edema) on the cells can be monitored as the system operates.  Small airway epithelial cells were 
first cultured in a culture media on the membrane until a confluent layer was formed, then 
exposed to air in the culture chamber.  Using a laser vibrometer, the magnitude of the pressure 
waves from the liquid plug flows was measured.  The Weibel model was used as a reference for 
the size and speed of the plug flow.  At a rate of 1 plug per minute, the results showed that only 
24% of the cells survived after 10 minutes, with most damage occurring downstream where the 
plug erupted.  This result shows the capabilities of lung-on-a-chip devices for representing 
pulmonary diseases in a microfluidic platform. 
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Fig. 2. Process of creating the liquid plug for the microsystem.  The process begins with A) air being 
produced in the upper inlet and liquid being produced in the lower inlet. Liquid is flowing from the lower 
inlet into the waste stream, so that the only fluid within the culture chamber is air.  B) The plug is started 
once the upper inlet is blocked, bringing liquid into the culture chamber. C) The plug is complete once 
the upper inlet is reopened and the liquid from the lower inlet is once again only flowing into the waste 
stream.  D) A complete picture of the plug system and the microfluidic chip can be seen, with the actual 
chip being highlighted in yellow.  The plug will slowly dissipate as it travels through the chip until it 
ruptures, E) releasing pressure waves in the system that can be monitored [25]. 
 
In a similar experiment designed to study the damage of lung cells by recreating liquid 
plug flow, a microfluidic device was developed by Tavana et al. to monitor the induction of 
pulmonary pressure on the culture system [26]. While the device shows a similar design to the 
previous design by Huh et al. for the integration of the liquid plug and the culture chamber, this 
project is designed to look at the role that surfactants play in the damage of lung cells.  
Deficiencies of pulmonary surfactants occur from the destabilization of liquid lining of small 
 
 
14 
airways causing osculating liquid plugs. In vivo, this is prevented by the secretion of a liquid 
surfactant from the alveolar epithelial cells. Human alveolar epithelial cells were used for the 
model, and cultured in F-12K medium. An air tank was used to supply air and a syringe pump 
was used to supply liquid. Size and duration of the plug flow was determined using a pressure 
transducer controlled by a DAQ board. During the experiment, the microchip was placed on a 
glass slide and observed on a microscope. Cells were stained with CellMask Deep Red plasma 
membrane stain to monitor the effects of the liquid plugs. The cells were imaged using an 
inverted florescence microscope.  A surfactant-free trial was run on the device, showing 
extensive injury to the lung cells. The surfactant, Survanta, was then introduced at 1 mg per ml 
of buffer for the next trial. Results showed a major decrease in the percentage of cell injuries in 
the system. For comparison, the surfactant-free trial showed a cell viability of 63% after three 
plugs, whereas the surfactant trial showed a cell viability of 81% after five plugs.  This in vitro 
pulmonary airway platform can be used to study cellular and sub-cellular effects in airway 
reopening.  
Built on the work of his previous design, Huh et al. [7] designed and fabricated a 
biomimetic microsystem in 2010 to not only mimic the cellular and diffusive properties of the 
lung, but also the macroscopic behavior, such as the expansion and compression of the system to 
mimic inhaling and exhaling. The microfluidic system consisted of two microchannels that were 
separated by a membrane of polydimethysilxane (PDMS), as opposed to a membrane of 
polyester in the earlier design. This lung-on-a-chip system is capable of mimicking the human 
lung's response to bacteria and inflammatory cytokines. The membrane was coated with ECM 
and human alveolar epithelial cells (NCI H441), and human pulmonary microvascular 
endothelial cells were cultured on the opposite side of the membrane (Fig. 3A). Two hollow 
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mirochannels on either side of the flexible membrane acted as vacuum chambers to simulate 
breathing movements (Fig. 3C, D, E). This design took advantage of the flexible PDMS 
membrane to better recreate physiological breathing (Fig. 3B). Through the study they also 
found that due to the mechanical strain of air being pulled in and out of the lung, the epithelial 
and endothelial uptake of nano particulates were enhanced and stimulated their transport into the 
underlying microvascular channel. To test their device, bacteria and inflammatory cytokines 
were introduced into the air, and human bloodborne immune cells were introduced into the 
blood-like fluid. It was observed that the lung-on-a-chip can mimic the innate cellular response 
to pulmonary infection of bacterial origin. However there are still differences between in vivo 
and the device, such as changes in air pressure and flow, cellular composition, and barrier 
thickness, that still need to be accounted for before it becomes a reliable alternative to animal 
testing.  
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Fig. 3. Design layout for lung-on-a-chip, showing A) a cross-sectional view of the device. Human 
alveolar epithelial cells are cultivated on the top of the membrane, while human pulmonary 
microvascular endothelial cells are cultivated on the bottom of the membrane. B) A view of the human 
lungs, showing the stretch and the resulting distribution of the air intake during the inhalation portion of 
the breathing cycle. C) The device consists of two PDMS layers with a porous membrane separating 
them. D) Once the layers are sealed, an etchant flows through the vacuum chambers. E) The finished 
design of the chip, with a quarter for scale [7]. 
 
The work done to mimic pulmonary edema in a human disease model-on-a-chip was 
expanded by Huh et al. [27] in 2012. The devices used in the study were slightly modified from 
previous work [7]. Once again PDMS was used as the top and bottom layers of the chip. The side 
chambers were created by etching the membrane layers in the side microchannels with 
tetrabutylammonium fluoride and N-methylpyrrolidinone, mixed at a ratio of 1:3. The solution 
was introduced into the side microchannels through inlet reservoirs by either hydrostatic pressure 
or vacuum suction. Etching took place until the thickness of the PDMS walls between the side 
chambers from the central culture chambers became thinner than 30µm. Afterwards, the side 
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chambers were washed with NMP to remove any PDMS etchant that remained.  After the 
alveolar epithelial cells were attached to the upper alveolar channel, culture media flowed 
through the device at 50µl/hour. Cells were grown for 5 days; on day 5 the culture medium was 
aspirated from the upper channel and a 50:50 mixture of epithelial and endothelial medium was 
introduced into the lower channel. This fed the alveolar epithelial cells on their basolateral side. 
For 15 days, epithelial cells were grown at an air-liquid interface. Just as in the previous device 
[7], the upper alveolar channel was filled with air and the lower microvascular channel was filled 
with liquid. Additionally, a vacuum was connected to the system to mimic breathing motion as a 
functioning human lung. It was shown that with the addition of cyclic mechanical strain to IL_2, 
leakage increased dramatically. The drug DSK2193874 was tested and shown that it could 
inhibit leakage. This demonstrates an additional step towards mimicking lung functions, and 
brings research one step closer to successfully predicting the activity of a new drug for cases 
involving pulmonary edema. The goal of having the ability to rapidly screen many drugs and 
conditions could one day become a reality once models can be connected to many other organ-
on-a-chip models. This could bring about a more accurate representation of how pharmaceuticals 
affect all areas of the body. 
Other mechanical properties were explored by the microsystem created by Douville et al. 
[28], who observed the effects of both solid and fluid mechanical stress on alveolar epithelial cells 
with a ventilator-induced lung injury (VILI). The device consisted of three major components: 
the alveolar chamber, PDMS membrane, and actuation channel. Human alveolar basal epithelial 
(A549, AEC) cells were culture in this model. The main contributor to solid mechanical stress 
for VILI is the cyclic stretching of the cells, while the main contributor to fluid mechanical stress 
is an air-fluid meniscus. Advancing versus receding menisci were observed for their stress 
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impact as well (Fig. 4.), with the confirmation that a receding meniscus causes more harm to 
cells than an advancing one. A finite element analysis (FEA) model was used to estimate the 
solid mechanical stress and the resulting model was proposed as a means to estimate the stress 
profile by measuring the maximum deformation of the system.  Results showed a viability of 
16.8% in the A549 cells and 32.5% in the AEC cells when exposed to both solid and liquid 
mechanical stress. This study prompts further research on understanding techniques to eliminate 
hazardous stresses in clinical settings.  
 
Fig. 4. Monitoring and computational fluid dynamic (CFD) analysis on the mechanical stresses of an 
advancing meniscus fluid plug versus a receding meniscus fluid plug. A) The streamlines of both menisci 
are displayed, with U = 1cm/s.  B) The half-meniscus profile was calculated and graphed.  The results 
show a smooth profile for the advancing meniscus (red), while the receding meniscus (black) contains 
abnormalities when focused on the edge of curvature (exaggerated display is boxed) that will increase the 
stress applied on the cell layer [28]. 
 
While these designs have improved the functionality of an in vitro lung design, a major 
problem with these designs is their poor permeability when compared to an actual working lung.  
This issue was addressed by Kniazeva et al. [29], who created a microfluidic design to maximize 
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gas transfer, with the goal of working towards creating an artificial lung or a lung assistant 
device. The design consisted of a small branched network of channels representing the 
microvascular system, with an ultrathin membrane separating the microvascular network from 
the channel representing oxygen flow. This design is repeated to create a multi-layer design with 
alternating levels of microvascular channels and oxygen channels. The ultrathin gas exchange 
membrane is used to maximize gas transfer efficiency while minimizing membrane-blood 
contact area, which is one of the main challenges in artificial lung technology. The network is 
designed to minimize blood damage, thrombosis, and inflammatory responses. The 
microvascular network also provides controlled wall shear stress and uniform blood flow. The 
device addresses many limitations seen in lung assist devices such as the Extra Corporeal 
Membrane Oxygenator (ECMO). Current ECMO devices have surface area to volume ratios that 
are 10 times less than the natural lining of a human lung.  Additionally, the gas diffusion distance 
in the ECMO is 10-30µm greater than the 1µm observed in the natural lining. Leaks of proteins, 
phospholipids, and lipoproteins often occur, which cause device failure. ECMOs also use non-
physiological blood flow pathways that can be unpredictable and uncontrollable. The membrane 
used in this device is thinner than the membranes used in ECMO devices, thus less surface area 
is required for equivalent oxygen transfer and the membrane is more gas permeable. Two 
different methods were used to test the device. The first test characterized the permeance of the 
PDMS membrane in a static medium. The second test analyzed oxygen transfer through the 
membrane. It was found through experiments that as the membranes became thinner, the 
permeance increases. The relationship was modeled with the equation:  
K=Q2/SA·ΔP       (1) 
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 where K is the permeance, Q2  is the  actual oxygen flow rate, SA is the surface area of oxygen 
transfer (was the same for each device), and ΔP is the transmembrane pressure. Following Eqn. 
1., it was found that K stayed relatively constant at a given membrane thickness. Therefore, as 
the transmembrane pressure doubled, the flow rate also doubled. The bilayer subunits that make 
up this device are easily reproduced and can be connected in different configurations. Membrane 
thickness can also be controlled and optimized. It was found that by using thinner sheets to 
create channels, overall oxygen transfer was increased. This device will be useful in artificial 
lung and lung assistant device applications that require high transfer rates of oxygen. 
Many lung assist devices today are limited to care unit settings because they are not 
implantable or portable.  From this, lung assist microdevices that utilize vascular networks are 
being designed, with the hopes that they can be implanted in the patient [30].  Sreenivasan et al. 
[31] developed a lung assist device that is designed to achieve physiologic flow through utilizing 
microfluidic vascular networks, which may allow this device to be implanted if it is impermeable 
to fluid.  Sreenivasan et al. aimed to improve their previous 8µm silicon membrane by designing 
the gas exchange membrane to be more permeable. They designed and developed a free-standing 
membranes (FSM) and composite membranes (CM) by means of initiated Chemical Vapor 
Deposition (iCVD). A control membrane of 8µm thick spun cast silicone was used to compare 
the two designs. Both devices were also tested for bond integrity. Sreenivasan et al. chose to 
work with p(nBA) and p(tBA) based chemicals for  free-standing membranes due to their ability 
to withstand bonding. The p(AA) was spun at 4000 rpm for 40s then baked at 150 °C for 2 
minutes to create a sacrificial layer. The p(AA) would then dissolve away, leaving the FSMs. 
The FSMs successfully remained intact during handling.  The FSM with a thickness of 5µm 
expressed a CO2 permeance 1.3 times higher than the control membrane.  An alternative to 
 
 
21 
ultrathin FSMs are composite membranes. CMs are composed of a highly permeable porous 
structure coated with a skin of a secondary polymer. These 0.1µm commercially available 
membranes provide mechanical stability to the device and minimize the chances of membrane 
rupture. The top skin layer allows gas transfer, while acting as a separation for liquid and gas. 
The CMs expressed CO2 and O2 permeance of 50-300 times the control membrane. These CMs 
are on the right track to achieving the permeable membrane needed for portable lung assist 
device. Defect-free thinner membranes (20-500 nm) are currently under development. 
Microfluidics can also be applied for the characterization of cellular responses, such as 
the correlation of the expression of Glucose Regulated Protein-78 (GRP78) and the resistance to 
anticancer drug VP-16 in lung cancer squamous carcinoma cell line SK-MES-1, researched by 
Siyan et al.[32]. Chemotherapy is hindered by cells that are resistant to the treatment. Little is 
known about the function of GRP78 because many in vitro detection methods are tedious, use 
large quantities of reagents, and require troublesome liquid handling procedures. The 
microfluidic chip contains an upstream concentration gradient generator and a downstream cell 
culture module. Their design was based on previous work by Jeon et al [33]. More will be 
discussed about cancer modeling on a chip in a later section. 
A chip modeling the nasal passage, specifically the nasal epithelium, was designed by 
Wang et al. [34]. This is useful because the nasal epithelial can be one of the first cells exposed to 
environmental agents.  Human nasal cilia beating behaviors, a defense mechanism of the airway, 
were investigated by testing its reaction to gaseous formaldehyde. A microfluidic system was 
used because it allows for good control and offers highly sensitive molecule detection. The 
microchip was made from molded PDMS and contained a square chamber (10mm x 10mm x 
30µm, width x length x depth) separating two straight channels. Human nasal epithelial step 
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progenitor cells (hNESPCs) were cultured on the device’s membrane located at the square 
chamber. A bottle containing formaldehyde was connected to one of the straight channels (inlet), 
while a withdrawing syringe pump system was connected to the outlet. Cilia beating frequency 
(CBF) was monitored at different gaseous formaldehyde concentrations (0.5 mg m-3, 1.0 mg m-3, 
3.0 mg m-3). While the 0.5 mg m-3 trial remained relatively stagnant, the 1.0 mg m-3 trial showed 
a CBF that increased immediately and continued to increase throughout the course of the trial. 
When exposed to high concentrations of 3.0 mg m-3 formaldehyde, it was observed that CBF 
slightly decreased instead of increasing. This may be due to the toxic effects on the epithelial 
cells.  The resulting experiment was shown to be a successful model of the nasal epithelium and 
has the potential to be used in clinical applications as well.  
 
2.3 Intestine 
Most oral drugs and nutritive substances are effective only after they are absorbed into the blood 
circulation through the intestine [35]. The evaluation of the intestinal absorption is important in 
the pharmaceutical and nutritional fields. The development of in vitro cell-based models for the 
intestine that mimic the mechanical, structural, and pathophysiological properties of drugs and 
nutrients is needed.  
Organ-organ and drug-drug interactions are very important when working with drugs. 
How one cell reacts to another based on the effects of a certain drug can either allow a new drug 
onto the market or not. For example, van Midwoud et al. [22] was one of the first to connect a 
liver and intestinal organ to allow for inter-organ interactions with applications towards toxicity 
testing. Bricks et al. [23] did a similar project using liver and intestinal cells as well.  
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A similar project that combined the liver with the intestine was done by Mahler et al. [36], 
who used a microscale microfluidic cell culture analog (µCCA) of the gastrointestinal tract (GI), 
as well as the liver, to predict drug toxicity. APAP was used as a model drug to test the group’s 
hypothesis that the passage and metabolism of APAP in the intestinal epithelial monolayer, 
followed by absorption into liver, would lead to low concentrations of glutathione and low 
viability of cells. Their goal was to create a complete in vitro human gastrointestinal tract model 
that is inexpensive, quick, and accurate to that of the human organs’ response to orally ingested 
drugs, chemicals, and the resulting cell-cell interactions. In vivo, the lining of the small intestine 
membrane is composed of enterocyte and goblet cells. The enterocytes make up most of the 
population and control the transport of molecules, while the goblet cells secrete a mucus 
designed to protect the lining of the membrane. The functions of these two cell types must be 
taken into consideration in order to produce a working drug absorption model in vitro. The cell 
line Hepg2/C3A was used to represent the liver, while a co-culture of Caco-2 and HT29-MTX 
cell lines at a 3:1 ratio was used to represent the intestinal cells. The design consisted of a GI 
tract µCCA that led into a systemic µCCA that represented the liver, fat, kidney, and bone 
marrow.  A peristaltic pump was used to control circulation and a reservoir compartment was 
connected to this system to control any sort of excessive pooling.  It is important to note that 
only the GI tract and the liver pathways contained cells.  The fat, kidney, and bone marrow 
chambers were only used to represent the distribution of fluid. The membrane was made of a 
polycarbonate with 0.4 µm pores and a Type I collagen coating. The cells were stained with 
calcein and monocholorobimane to visualize the monolayer integrity. Trials in this system were 
run for a course of 24 hours. The results showed an inverse relationship between the 
concentration of APAP and the concentration of glutathione and cell viability. The products of 
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APAP, APAP-GLUC and APAP-SULF, were monitored throughout the trials as well.  Results 
showed that APAP-GLUC was produced fairly quick at the beginning of the experiment, but 
remained constant after the sixth hour.  APAP-SULF showed concentrations that were ten times 
higher than that of APAP-GLUC for the first six hours, with a steady increase throughout the 
entire trial. This experiment showed GI tract-liver characteristics that showed they were able to 
digest APAP, with close observation to their viability and the products formed in the reaction.  
While they still are not able to produce the same levels of digestion as an in vivo equivalent, 
these results are fairly agreeable with in vivo results. 
There have been many studies on the microfluidic in vitro design of the gastrointestinal 
tract and stomach for toxicity testing, drug testing, and mimicking key functional and structural 
parts. The use of hydrogels as a platform for cultivated cells in a GI tract design has been 
explored as well [37]. Sung et al. [38] developed a 3D collagen scaffold that mimicked the human 
intestinal villi. The technique used to create the hydrogel involved laser ablation to carve out 
holds on a plastic mold.  This plastic mold was used to create a reverse-mold out of PDMS.  
Then, the reverse-mold PDMS was used to create a second mold that was made of calcium 
alginate.  The hydrogel was built off of this mold, which eventually dissolved. The molds and 
structures were built with dimensions mimicking that of intestinal villi. Caco-2 cells were 
cultivated on the hydrogel villi, resulting in an in vitro system with close structural similarities to 
human jejunal villi. Cells could either be encapsulated in the hydrogel or seeded into the 
structure to be cultured. Collagen and polyethylene glycol diacrylate (PEG-DA) were used as the 
two types of hydrogels. Their system is simple and does not require expensive or complex 
equipment, which is a requirement for most microfabrication methods. While a microfluidic 
analysis was not done on the hydrogels, observation of the culture within the hydrogels revealed 
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a successful layer of Caco-2 cells. With an analysis of flow from both sides of the device, a study 
of the dynamics of drug absorption in the GI tract can one day be done.  
Although some models are used for the testing of toxins or drugs, a model for bacteria is 
rarely seen in microfluidic models. Kim et al. [39] created a model that had bacteria grown and 
added to healthy intestinal cells to see how they reacted. Instead of modeling the gastrointestinal 
tract for its functions and mechanical properties like with previous researchers, a GI tract 
infection was chosen as the focus. The system mimics the sequence of events in a gastrointestinal 
(GI) tract infection, specifically the invasion of bacteria on the intestinal cells. In the human 
body, a healthy GI tract can be defined by the balance of the interactions between the commensal 
bacteria and the intestinal epithelial cells.  Pathogens often out-compete the bacteria and attach to 
the epithelial cells and begin an infection even though there are more commensal bacteria than 
pathogens. The molecular signals that are given off by the GI tract allow the commensal bacteria 
to prevent pathogen colonization or infection. In the model, this relationship is studied with a 
microfluidic device contained a co-culture of epithelial cells and bacteria. The group used E. coli 
as the prototypic commensal bacterium and HeLa S3 cells as the model for the intestinal 
epithelial cells. The pathogen used was E. coli O157:H7, a harmful strain of E. coli. The device 
consisted of a large chamber used to culture the epithelial cells and two “islands” used to culture 
bacteria. The two islands were located 1000 µm apart and were lowered and raised on a 100 µm 
thick PDMS wall. The cells grew a confluent layer and the bacteria produced a biofilm. Then the 
pathogen was introduced to the biofilm, followed by exposure of the epithelial cells. Resulting 
data showed a specific signal, indole, as having a huge effect on the resulting HeLa cell viability 
(which is directly correlated with the level of infection from the pathogen).  Commensal bacteria 
that lacked this signal produced half the viability than when it was present.  A trial in which 
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500µM of indole was directly introduced to the pathogens also showed an increase in HeLa 
viability, but not to the extent of a natural signal.. The group states that future work in 
determining biofilm thickness and the extent of the pathogen colonization are the next steps 
needed to better reproducing their model.  
In 2012, the group of researchers from Kim et al. [40] developed a “human-gut-on-a-chip” 
that utilizes dynamic motions on the microdevice to better mimic the structure and function of 
the living intestine. This dynamic environment is created by the flow of the fluid through the 
channels, as well as the application of cyclic strain by use of vacuums within side chambers to 
mimic peristaltic motion. The design is similar to that of Huh et al. “lung-on-a-chip” design [7], in 
which two side chambers are utilized as vacuums to control the motions that the organ 
experiences in vivo (Fig. 5A, B, C). This time, these distortions are used to represent the 
peristaltic motion experienced by the intestines (Fig. 5D, E). The upper and lower microchannels 
are 150µm high x 1000µm wide, and are separated by a 30 µm thick PDMS membrane that has 
10 µm pore size. Caco-2 cells were used to represent the intestinal epithelial cells, and were 
cultured on a PDMS membrane coated with ECM. Trials consisted of a Transwell plate for 
control and the microfluidic device containing just fluid flow, just mechanical distortion, and 
both. Results showed faster and higher quality Caco-2 cells in the trials using the microfluidic 
device. In the absence of fluid flow, the cells in the microfluidic trial resembled those in the 
Transwell plate.  Additionally, the trial containing both fluid flow and mechanical distortion 
grew cells containing folds that resembled intestinal villi. To simulate the GI tract more 
accurately, cells obtained from a strain of Lactobacillus rhamnosus GG (LGG) were used to 
simulate the microbes native to the intestines.  The co-culture displayed greater integrity than the 
Caco-2 monolayer in the prior trials when exposed to fluid flow and mechanical distortion on the 
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microfluidic chip. Therefore, this design was a success in introducing two variables to a gut-on-
a-chip model: the integration of microbial cells native to the intestines and the dynamic motions 
inherent in the organ. Kim has explored these ideas further in other research papers [41]. 
 
Fig. 5. Layout for Gut-on-a-chip, with a) two co-current microchannels containing a membrane with 
cultured gut epithelium. Two vacuum chambers are located on either side of the device. B) An aerial view 
is shown of the actual device. C) A cross-sectional view is shown, with an aerial view of the membrane. 
D) When the vacuum chambers are active, mechanical strain is exerted on the device (upper two images). 
Cells showed that they would deform due to mechanical strain. The image on the bottom left circled in 
red is an epithelium cell before strain and the image on the bottom right circled in blue is an epithelium 
cell after strain. Note the image to the right showing an overlap image of the two, with the deformed cell 
clearing showing a larger width. E) Graphical results of the strain of both the substrate and the cells as a 
function of the applied pressure of the vacuums [40]. 
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In contrast to Kim et al., the experiment done by Kimura et al. [42] used polarized Caco-2 
intestinal cells in their microfluidic system. Polarized cells are known to mimic human organs, 
especially the human intestine, with much better accuracy.  The developed microfluidic system 
was able to have long-term perfusion within the cell culture, as well as integrated optical fiber 
inserts used for fluorescent measurements within the device. The device contained two PDMS 
layers separated by a semipermeable membrane coated with collagen.  A micropump controlled 
by a stir-bar was used to induce circulation of the medium. Once again Caco-2 cells were used to 
represent the intestinal cells and were cultivated on the apical side of the membrane. On the ninth 
day of cultivation, a confluent monolayer of cells was observed over the membrane. The cells 
were able to be cultured for up to 30 days and formed a tight monolayer. Transportation qualities 
were recorded by introducing rhodamine 123 into the medium, along with fluorescent beads, and 
recording the effects through the optical fibers.  The results showed flow capable of long-term 
perfusion within the system. The functionality of the device and the measurements found through 
the results of the rhodamine 123 show that this has the potential to be a useful platform for drug 
screening as well as toxicity testing.   
Some microfluidic systems are complex or have operating parts that not everyone can 
use. For this reason, it is important to think about simpler designs for microfluidic systems. 
Imura et al. [43] developed a microchip-based system that mimicked the human intestine. They 
had a microfluidic system to evaluate the intestinal absorption, with less cells and samples used 
and a shorter testing time. The design of the system was a two-tiered microchannel separated by 
a monolayer of Caco-2 cells that are cultured on a permeable membrane. The device had two 
PDMS sheets, each with its own microchannels that were 1.5mm in width and 200µm in height. 
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The channels connected the upper and lower side of the PDMS sheets together. The upper 
channel worked as a microchamber for the cell culture. The membrane was made of a 
polyethylene terephthalate sheet that had 1µm sized pores and was coated with type I fibrillar 
collagen. Permeation tests were done to test the drug permeability of cycliphophamide (CPA), 
using Lucifer yellow as a fluorescent marker. They also set bubble traps in the injection ports to 
prevent incursion into the chip. Since past structures had leaked the Lucifer yellow to the lower 
channel because of loose PDMS sealing, a new design was made. In this new design, the lower 
PDMS sheet and the membrane were tightly bonded to avoid leakage onto the other channels. 
Due to the cells becoming damaged because of unstable medium flow, the group cultured the 
cells statically and the medium was replaced on a daily basis. The Caco-2 cells formed a 
confluent cell sheet, and the Lucifer yellow could not permeate the membrane, while the CPA 
did. Good results were obtained with a lower flow rate; however, it also proved to be very time 
consuming. The Caco-2 cells reached confluence after 3 days and then remained this way for 10 
days in the microchamber. When compared to conventional in vitro experiments, this system had 
practical characteristics of intestinal absorption. 
Drug testing is one of the most important factors in intestinal microfluidic applications. 
Although many groups have used drugs for testing, none of them have used an array of drugs to 
study the effects they have in relation to each other. Yeon et al. [44] developed a microfluidic 
device to test drug permeability in the intestinal epithelial cell membrane. Researchers looked at 
10 different drugs in order to test their permeability and compare the results with in vivo 
permeabilities. Instead of a membrane, the device trapped Caco-2 cells in microholes and 
measured the permeability of the drugs from there. The microfluidic device consisted of 
channels, each with an inlet and outlet, and a microhole array separating the two channels, and a 
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channel for mixing. The microholes are 3µm in diameter, 5µm in height, and 30µm in length. 
The microchannel height was 25µm and most animal cells with a diameter of 5-15µm could be 
trapped. The Caco-2 cells are imported into only one of the inlets, while a buffer is imported 
through the other.  Different flow rates from the two channels created a pressure difference that 
trapped the cells once they reached the microhole array. Once this occurs, the drug intended for 
testing is imported through the inlet originally containing the buffer. The drugs are absorbed by 
the cells in their channel, and travel through the mixing channel and into the outlet. The 10 drugs 
that were used for the experiment were: propranolol, naproxen, furosemide, antipyrine, 
verapamil, atenolol, piroxicam, hydrochlorothiazide, cimetidine and carbamazepine. The Peff 
values that were measured in the microfluidic device were not the same as in vivo; however, they 
were still highly correlated with the permeabilities in the human intestine. This system reduces 
the assay time due to a non-complex system, and because there is no cellular membrane. The 
results found here has the potential to be used in predicting actual human permeability values of 
drugs, as well as a tool for drug discovery and toxicity testing. 
 
2.4. Kidney 
The renal transporters are located in the apical and basolateral membranes of the tubular 
epithelial cells. The effect of fluid shear stress on the cells is less understood than other major 
cells [45]. The renal epithelial cells experience mechanical forces due to variations in the urinary 
flow rate.  
With toxicity being a main interest in the drug testing field, the kidney has been an organ 
of increasing interest for such tests. The kidney is exposed to fluid shear stress and it acts as a 
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filtration system for the blood, as well as a vessel for the removal of toxins. The kidney transfers 
the toxins to the bladder, where they are then removed from the body during urination. Recall 
that Shintu et al. [20] used the liver and kidney, as well as cell co-cultures, to study their metabolic 
responses to various toxins.  However, this section will focus on research done solely on the 
kidney [46].  One of those is Baudoin et al. [47], who developed a microfluidic microchip that 
contained functional living cell microchambers that allowed for continuous cell feeding and 
waste removal. Their experiment consisted of a Madin Darby Canine Kidney (MDCK) cell 
culture on a PDMS-based cellular microchip that can be used for in vitro renal applications. 
Additionally, a toxicity study was performed on the microchip for the demonstration of large-
scale toxicity applications. The group coated the PDMS chip in Fibronectin (extracellular matrix 
protein). The first PDMS layer with the microstructures contained a series of 300µm x 300µm x 
100µm microchambers and 400µm x 150µm x 100µm microchannels, which were all contained 
inside a cell culture chamber. The second layer of PDMS was used to close this cell culture 
chamber. Culture media was brought into the microchip system through a culture medium tank, 
and the flow was induced through a peristaltic pump. These devices were formed as a circuit, 
thereby creating a perfusion loop. For toxicity tests, ammonium chloride was used. The initial 
experiments tested the viability of cells in the system as it ran inside a CO2 incubator for various 
flow rates (0, 10, 25, and 50 µL/min). The results showed it was able to run while keeping a 
viability above 90% for almost all flow rates, except for at 50µL/min. At 50µL/min, the cell 
detached from the surface after a 24 hour perfusion and viability was found to be below that of 
10%. Cell density tests showed that at static conditions, the number of cells stayed roughly the 
same, regardless of their initial count.  At flow conditions, slight proliferation of cells was 
observed at flows of 10µL/min and 25µL/min. The addition of ammonium chloride as a toxicity 
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agent caused the reduction of cell proliferation.  This reduction was most prevalent in the 
10µL/min trial. The addition of ammonium chloride also led to an increase in the consumption of 
glucose and a decrease in the production of ammonia.   
The integration of fluid shear stress is an important factor that can increase the relevance 
of an in vitro model. Jang et al. [48] developed a multi-layer microfluidic device that utilizes 
fluidic shear stress for a more complete renal model. They used primary rat inner medullary 
collecting duct (IMCD) cells as their model to be cultured inside the microfluidic channel. A 
fluidic shear stress was applied to the device to generate a realistic environment for the cells. The 
device consisted of two layers of PDMS, with a polyester porous membrane between them.  The 
bottom layer of PDMS was used as a reservoir, while the top layer contained a microfluidic 
channel that would be used for fluid flow. After 3 days of culture, the cells were brought into the 
system and a fluid shear stress was applied for 5 hours using a syringe pump. After the shear 
stress was applied, 1mM of hydrogen peroxide solution was added to the fluid regions to test the 
cell viability. Hydrogen peroxide was also added to a control culture that was cultivated on a 
glass surface separate of the device. The results showed that after 2 hours of treatment, the 
device under fluid shear stress already displayed a significantly higher viability than the glass 
control. Additionally, the system showed accurate cell separation associated with its cell 
polarization. Molecular transport was also analyzed by applying vasopressin and aldosterone into 
the lower PDMS reservoir to induce hormonal stimulations into the system. Vasopressin is able 
to induce water transport, while aldosterone induces NA transport. Both of these results agree 
with in vivo expectations. This system can be used as a model for diseases like diabetes or 
edema, as well as a model for studying renal physiology. 
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In the year 2010, Jang studied the kidney cells and showed the polarization and transport 
of the primary rat inner medullary collecting duct (IMCD) cells as well as the application of fluid 
shear stress (FSS). Now in the year 2011, Jang et al. [49], developed a ‘collecting-duct-on-a-chip’ 
to further investigate the effects of changes within a renal environment. The role of the collecting 
duct in the kidney is mainly to maintain homeostasis of fluids through transportation across its 
membrane. Specifically, the role of the protein aquaporin-2 (AQP2) was observed under these 
altered conditions due to the major role it serves in water transport across the membrane.  
Additionally, the role of the actin cytoskeleton present in in vivo collecting ducts (F-actin) is 
explored in the model.  Like their previous design, the main components that made up the chip 
consisted of a PDMS reservoir and a PDMS layer complete with microchannels for active fluid 
flow, as well as a polyester membrane separating them. Fluid shear stress, hormonal stimulation, 
and an osmotic gradient across the membrane will serve as the active changes within the system. 
Fluid shear stress at 1 dyn cm-2 and arginine vasopressin stimulation (AVP) were applied in the 
microfluidic chip for trials consisting of F-actin within the IMCD cells. A strong fiber network 
was observed roughly 1 hour after the start of the trial, with a slow depolymerization occurring 
up until hour 5, when the F-actin was fully depolymerized.  It was also observed that if system 
was left undisturbed after depolymerization, the F-actin would repolymerize after roughly 2 
hours. Additionally, the application of an osmotic gradient was shown to lead to a full F-actin 
depolymerization. This system can be used as a tool for drug screening of the regulation of 
AQP2 as well as being an important model for fluid homeostasis. 
Most recently, Jang et al. [50] made a microfluidic device that mimicked the functions of 
the human proximal tubule using primary human kidney epithelial cells. Although they only used 
one type of cell, their research brings forth more information that is needed to help the problem 
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of accurate drug development. Their system, just like others, can be used to replace two 
dimensional cell culturing and animal testing for the ability to test for toxins in organs. The 
device shows many similarities to their previous design [49]. Once again, the main components 
consisted of a lower reservoir and an upper microfluidic channel with a porous membrane 
containing ECM collagen separating the two. The cells were cultivated on the porous membrane, 
in which well-defined monolayers were observed after 3 days for both static and fluid conditions. 
The addition of fluid shear stress created an even more realistic cell layout, with a system of cell 
columns consistent with their in vivo cell polarity (Fig. 6.). Analysis of the system showed that 
the levels of albumin uptake, expression of brush-border alkaline phosphatase, and glucose 
transport were greatly increased when flow was introduced into the system. To observe toxicity 
effects, the cells were treated with cisplatin for 1 day and then were allowed to recover by 
keeping them drug free for 4 days. The magnitude of recovery was significantly higher in the 
system containing flow. The use of primary human kidney epithelial cells, along with a model 
used in static and dynamic conditions, presents a method that shows promise for renal toxicity 
analysis. 
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Fig. 6. Design layout for the device, showing A) a cross-sectional view. The device mimics the human 
proximal tubule of the kidney (pictured below). Human proximal tubuluar epithelial cells are cultivated 
on top of the membrane, with tubular flow occurring on the apical section, and interstitial fluid located 
on the basolateral section. B) The device shown layer-by-layer. Two design consists of an upper layer 
containing a microfluidic channel and a lower layer containing a fluid reservoir [50]. 
 
Since fluid shear stress is very important in the function of the kidneys, Frohlich et al. [51] 
developed a microscale tissue modeling device (MTMD) to represent an accurate renal system.  
This device focuses on utilizing fluid shear stress and a topographical pattern to mimic its in vivo 
counterpart. The device consisted of a lower silicon plate that contained sub-micron 
topographical features such as grooves and pitches, and an upper PDMS layer containing a 
microfluidic path. The human renal proximal tubule cell line HK-2 was chosen to represent the 
tissue. The HK-2 cells were stained with ZO-1 fluorescence to analyze the tight junction 
formation. Blank substrates in the presence of FSS showed a much lower ZO-1 intensity and a 
more disorderly array of cell structure.  Topographic substrates without FSS showed a higher 
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ZO-1 intensity and a better array of the cell layer. In the presence of both, the cells showed a 
well-defined tight junction with good intensity.  Therefore, while FSS seems to play a bigger role 
in the modeling of the kidney, a combination of both yields the best results. 
The role F-actin plays in the transportation of nutrients across the membrane was also 
analyzed by Ferrell et al. [52], who used electrodes designed to take TEER measurements to 
analyze a working kidney bioreactor under fluid shear stress conditions. TEER measurements 
have shown to provide excellent inside into the tight junction permeability properties of a cell 
culture. Additionally, transportation properties were analyzed, with special focus on the structure 
of tight junctions (ZO-1) and cilia formation (acetylated α-tubulin) within the cells, and the F-
actin cytoskeleton array that facilitates transfer. The device consisted of an apical chamber 
complete with 8 microfluidic channels and a basolateral chamber used as a reservoir. An array of 
200µm diameter posts was used to support the membrane on the bottom chamber and allow fluid 
transport. A polycarbonate membrane was connected to separate the two chambers. A perfusion 
circuit was created, consisting of the bioreactor, a perfusion pump, and a medium reservoir, all 
connected through silicone tubing. For TEER analysis, electrodes were inserted within the 
tubing, with the ends exposed within the bioreactor. Additionally, all trials were conducted 
within an incubator. A shear stress of 1 dyn cm-2 was used for fluid shear stress trials.  Both 
human renal epithelial cells (HREC) and MDCK cells were cultivated on the membrane. Initial 
culturing results showed that the MDCK cells were able to form a monolayer within 3-5 days, 
while the HREC cells took 10 days. Staining techniques were used to analyze the formation of 
tight junction proteins, cilia, and F-actin (HREC only). Both ZO-1 proteins and acetylated α-
tubulin were observed in the model, showing well-defined borders and distinct formations (Fig. 
7a-b). Additionally, the role of F-actin in static conditions showed a normal layout of F-actin 
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(Fig. 7c), while fluid shear stress conditions showed the F-actin surrounding the cell (Fig. 7d). It 
is believed that this is a normal response of the cytoskeleton to shear stress and is similar to what 
happens in the cells of humans. The system was then monitored with the addition of Ca2+ into the 
medium, which is known to have a positive effect on the structure of tight junctions. A switch 
technique was used to measure transient changes, where the system would switch between using 
a medium containing normal levels of Ca2+ to low levels of Ca2+.  After analysis, normal levels 
of Ca2+ were restored and the system was allowed to recover. The switch from normal to low 
levels of Ca2+ showed a TEER that contained 45% of its original resistance. Using inulin as a 
marker, the results showed a large increase in leakage rate when the switch to low Ca2+ levels 
was made (from 0.09 ± 0.03 µg cm-2 min-1 to 0.39 ± 0.09 µg cm-2 min-1), showing the potential 
breakdowns of cell interactions when transient changes are applied. 
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Fig. 7. Immunofluorescence staining results depicting the formation of a) MDCK monolayer and b) 
HREC monolayer, each containing well-defined tight junctions (green outline) and primary cilia (red 
dots addressed by arrows).  Additionally, HREC was stained for F-actin analysis under c) static 
conditions and d) fluid shear stress conditions. Arrows in Fig. 7c indicate F-actin fibers. Scale bars in 
Fig. 7b and Fig. 7d are at 25µm [52]. 
 
Analysis of mass transfer has also yielded results [53]. Ramello et al. [54] investigated the 
properties of mass transfer in a microfluidic kidney model. They also analyzed the transportation 
by using different drugs. The study used MDCK cells on a polyethersulfone (PES) membrane 
inside a PDMS chip. The chip contains an upper and lower chamber, each containing an inlet, 
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outlet, peristaltic pump, and filtration chamber in co-current circulation. This was done to create 
a system in which one chamber contains a reservoir of filtrate while the other contains retentate. 
The retentate circulation would initially contain the molecule used for inspection, while the 
filtrate circulation would capture the filtered molecule. Molecules used for this experiment were 
chosen based on their variety in size.  Caffeine was used as a small marker, vitamin B12 was 
used as a medium marker, and albumin was used as a large marker. The value of cell membrane 
permeability before mass transfer studies was measured as being equal to 1.8 ± 0.2 mL/(min cm2 
bar), and the value without cells was 9 ± 3 mL/(min cm2 bar). Trials involving mass transfer were 
compared with mathematical models, with cells and without cells on the membrane. The results 
showed an inverse relationship with molecular weight; there was a notable increase in mass 
transfer as the molecular weight decreased. Mass transfer through a membrane without cells 
yielded higher rates of mass transfer for all trials. When treating the cells as a separate diffusive 
layer, the mathematical models fit the experiment results perfectly. In an attempt to model 
toxicity in the system, acrolein was used at varying concentrations.  For each molecule tested, 
there appeared to be a threshold in which acrolein did not play a factor in the mass transfer of the 
system.  The larger the molecular weight, the higher the threshold. Above this threshold, the 
diffusive coefficient was found to be higher than trials without acrolein. A second threshold was 
observed, in which surpassing it yielded a time-dependent mass transfer rate. The permeability of 
the membrane was measured after the acrolein trials, which revealed an increased permeability 
of 8 mL/(min cm2 bar). Thus, these experiments showed the effects of molecular weight and 
toxicity on the permeability and mass transport properties of the system.  These results agreed 
with past research and mathematical models and have shown that they can be a useful model for 
modeling mass transport on a renal biochip. 
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2.5 Heart 
The function and development of the heart mainly depends on the response of the cardiac cells 
and the mechanical stress. In order to have new successful drugs and medicine, it is important to 
understand the biological functions of the heart. Current cell culture systems fail to accurately 
represent the physical, mechanical, and biological functions of the heart. There have been studies 
that have tried to model the heart; however, most are two dimensional, and although they do 
show some mechanical properties, they are not the best for accurately mimicking the human 
heart as they do not have complete heart properties and do not allow for fluid flow or similar 
work [55] . For this reason, three dimensional microfluidic systems for the heart are being 
explored as well.  
Many groups have designed various systems to model the human heart and to mimic the 
key mechanical functions and properties [56]. Due to the advantages of 3D microfluidic systems, 
there has been a shift towards using these designs to represent cardiac situations [57]. Giridharan 
et al. [58] developed a model designed to replicate physical loading in the left ventricle. This 
microfluidic cardiac cell culture model (µCCCM) contains a cell culture chamber, a pump, a 
collapsible pulsatile valve, and an adjustable hemostatic valve.  The cell culture chamber consists 
of a PDMS membrane between two polycarbonate plates, milled with microfluidic channels to 
create perfusion through the membrane. The embryonic cardiomyoblast cell line H9C2 was used 
for cultivation on the membrane. The pump serves the purpose of supplying flow, and therefore 
shear stress and fluid transport, to the system. The pulsatile valve is used to produce mechanical 
stress into the system in the form of pressure build-up in the cell culture chamber, resulting in the 
stretching of the membrane. A closed valve builds pressure while an open valve relieves 
pressure, thereby being capable of representing cardiac preloading. The hemostatic valve is used 
 
 
41 
to control flow resistance, and is a representation of afterloading. These devices are connected as 
a circuit to provide circulating fluid flow. This device was first tested by applying different levels 
of pressure for a variety of membrane thicknesses.  The strain was found to be inversely 
proportional to membrane thickness, displaying a 20% strain for a 139µm thick membrane and 
60% for a 93µm thick membrane.  Next, the device was characterized for normal conditions, as 
well as for abnormal conditions such as: heart failure, hypertension, hypotension, tachycardia, 
and bradycardia. The simulation of cardiac disorders was done through the programmable valves 
connected to the system. Values obtain from these trials depict fairly comparable results with 
their in vivo counterpart. When comparing the cellular make-up between static trials and the 
trials within the µCCCM, results showed that the static culture make-up resembled fibroblasts, 
with randomized F-actin, while the µCCCM displayed a rectangular, boxy make-up with aligned 
F-actin. This shows the capabilities inherit in modern microfluidic cardiac models, especially 
when considering abnormal heard conditions. 
When dealing with in vitro microdevices for tissue engineering or drug delivery [59], 
external power sources are depended upon to supply energy into the system.  However, if the 
device requires implantation into an in vivo source, external power sources must be eliminated. 
Tanaka et al. [60] fabricated a micro spherical pump made from cardiomyocytes to represent the 
heart functions. The hollow sphere was created by inserting a capillary tube through the entirety 
of a sugar ball, so that both ends of the capillary could be observed outside of the ball.  A layer 
of PDMS was applied around the sugar ball, and the capillary tube was pulled back to allow a 
second capillary tube to connect to the other side, and both tubes were glued into place. A pump 
was applied through one of the capillary and water was introduced to dissolve the sugar.  This 
resulted in a hollow sphere with a thickness of 250µm (Fig. 8a). Rat cardiomyocyte cells were 
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cultured and placed on the surface of the PDMS sphere. Spontaneous pulsating was observed 
within one hour of incubation, which eventually became periodic beating (Fig. 8b).  Fluoro 
Sphere particles were introduced into the medium for tracking. The results were determined with 
a particle displacement data set which estimated the parameters for the performance of the fluid 
bio-actuation. The following equation was used to describe the change in microchannel volume 
as a function of the change in chamber volume:  
Δv=1/2ΔV     (2) 
where Δv is the volume change in the microchannel and ΔV  is the volume change in the 
chamber. Using Δv=0.5𝑥𝑥𝑥𝑥r2 as an approximation due to its circular cross-section, where x is the 
displacement of particles near the capillary center and r is the inside radius of the capillary, ΔV 
was found to be 2.2nL.  From there, the following equation was used: 
Q=f ΔV    (3) 
where Q is the flow rate and f is the beat frequency. They found that f was 0.6Hz at 37º C, which 
resulted in a final Q value of 0.047 µL min-1. Long-term trials showed that the device could be 
functional for up to 5 days. They compared it to other typical micro chemical systems and 
showed that it is possible to use the system Tanaka et al. made in micro chemical or biochemical 
applications. They confirmed that their device was flexible and biocompatible and very similar to 
other polymer pump actuators. They concluded that if their heart device functioned continuously 
for at least 5 days, the cells of cardiomyocytes that were inside the sphere would live for that 
amount of time as well. They stated that this can be used to mimic animal hearts; however, it is 
worth noting that there are multiple chamber valves and walls required for this process. To do 
this they used an in situ laser photo-fabrication technique. These results and their microspherical 
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heart pump are very important as it is a step towards having electric powerless bio-actuators for 
fluids in implants and also for micro model cardiovascular circulatory systems for monitoring 
applications. 
 
Fig. 8. Diagram of the micro spherical heart pump, shown in A) a full view, diplaying the components of 
the device and medium brought in through port A and expelled through port B. Additionally, B) a cross-
sectional view is shown. The layer containing the rat cardiomyocytes can be seen, with red arrows shown 
to display their contracting nature on top of the PDMS sphere [60]. 
A different study to that done by Giridharan et al. and Tanaka et al. was done by Li et al. 
[61], who fabricated a microfluidic chip that uses integrated acoustic wave sensors to analyze 
cardiomyocyte contraction. The sensor works by applying a voltage to the electrodes located on 
both sides of a flat quartz crystal plate. The voltage induces acoustic waves from the crystal due 
to the piezoelectric effect. These acoustic waves will be produced in the thickness-shear mode 
(TSM) and applied to the cardiomyocyte cells. Any change in stiffness will result in a modified 
resonant frequency. This method can be used to identify pulsating properties of the cells. The 
device consists of an upper glass plate milled with microfluidic channels and a bottom quartz 
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crystal plate acting as the TSM sensor. Cells were fit into the channels of the glass plate. Data 
showed that the device without the channel plate was capable of reacting to changes in the 
system for all parameters.  Changes in the system include additions of cell suspension and a bath 
solution. The parameters were shown to make corresponding changes at the intervals at which 
the changes in the system were applied. The experiment was then run using the channel plate.  
The results showed mixed results that only proved that the system wasn’t fully capable of 
responding to the acoustic waves. The group believes that offsetting contractions may have been 
one of the underlying problems in the experiment, and therefore a shorter interval between data 
points may be able to rectify this problem. 
While not falling into the classic mold of organ-on-a-chip systems, the method of testing 
extracting organ tissue instead of cultivating cells is another potential method for understanding 
organ function in vitro. Owaki et al. [62] proposed a microvascular connection method called the 
“suction-induced vascular fixation method” or SVF method. They were able to use tissue from 
an extracted chick heart and connect it to their microfluidic system. The SVF method consists of 
using a suction technique to bring all the blood vessels through a microfluidic device.  This 
constrains the vessels so that they are easily manipulated and can be analyzed with less degrees 
of freedom. The microfluidic device consists of a PDMS layer containing holes designed for 
integration with the blood vessels of the chick heart, as well as a perfusion chamber to maintain 
functions of the organ. Due to the variability and uncertainty of blood vessel diameters, the 
device allows several vessels through one hole if the vessels prove to have a smaller diameter 
than expected, and can also be rejected if the vessel diameter is too large. While the main goal of 
their experiment was to design an alternative method to handle the analysis of organ tissue, an 
addition test was done in which a solution was sent through the device and into the embryonic 
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heart.  The results showed that a periodic circulation could be achieved through this method, and 
the heart was able to periodic beat using this method. 
 
2.6 Vasculature  
Endothelial cells that line blood vessels are designed for functions such as: facilitating blood 
flow, enabling nutrient transfer through the vessel, and regulating surrounding tissue growth [63]. 
A viable microcirculation is required in in vitro models if we are to interconnect organs.  This 
will be especially important if a “human-on-a-chip” design is created. However, this section will 
focus on a microfluidic model for isolated vasculature. It is vital to have a realistic in vitro model 
for drug development and the study of cell-cell interactions. 
Research into 3D in vitro vasculature has produced a variety of results [64].  However, the 
design of functional artificial vasculatures has been a difficult hurdle to overcome.  Borenstein et 
al. [65] have specifically addressed this issue in their design. The microchip design displayed one 
inlet and outlet, with a bifurcating microchannel network stemming from each end and joined 
such that the design showed a symmetric pattern. To better mimic human vasculature, all 
channels were designed with circular cross-sections, and each new generation of bifurcation had 
a smaller cross-sectional area than the last (Fig. 9). The diameters chosen for each subsequent 
channel were based off of Murray’s Law. Polystyrene was used as the material for the chip due 
to its stability and a better understanding of the surface properties. Two layers, each containing 
the network with cross-sectional channels, were created using an electroplating technique. 
Human umbilical vein endothelial cells (HUVEC) were cultivated on the inner surface of the 
channels. Results showed a stable and consistent monolayer throughout the channels. Thus, the 
goal of creating a microfluidic chip capable of accurately representing human vasculature proved 
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successful. While flow was not examined in this experiment, the circular cross-sections and 
smooth transitions between bifurcations and diameter changes have potential for use in 
microfluidic vasculature chip designs. 
 
Fig. 9. Image taken of the device. A network of bifurcating channels, each level containing a diameter 
smaller than the last, is shown. The scale bar is displayed at A) 1mm and B) 500µm [65]. 
In pursuit of a physiologically similar vasculature model, considerations such as multi-
cell interaction and dynamic stress on the system should be considered. The design created by 
Srigunapalan et al. [66] looked at the effects of shear stress, monocyte-EC adhesion through TNF-
α stimulation, and monocyte transmigration on a microfluidic vasculature system. The device 
consists of two PDMS layers, with the top layer displaying a straight microchannel and the 
bottom player displaying an S-shaped microchannel. A polyethylene membrane containing 8µm 
pores is used to separate the two layers. Circulation of flow was provided through a peristaltic 
pump that would take media from a reservoir compartment and feed it through a damper, 
followed by the microfluidic chip, then back into the reservoir, completing the cycle. The 
purpose of the damper was to force continuous flow (as opposed to pulsatile flow) into the chip. 
Porcine aortic endothelial cells (PAEC) were chosen for the EC and were cultivated on the top of 
the membrane. Initial trials tested this system under static and dynamic conditions, with dynamic 
conditions providing a shear stress of 20 dynes cm-2. Results showed elongation of the PAEC for 
dynamic trials.  Further trials introduced TNF-α stimulation into the culture, followed by 
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monocytes (RAW264.7 cells) applied with fluorescent dye. Monocyte adhesion was tested as a 
function of both TNF-α stimulation and its static/dynamic state.  Results showed that TNF-α was 
the biggest factor in monocyte adhesion, while the trials under fluid shear stress proved to have 
slightly better adhesion capabilities than their static counterparts. Trials done for testing 
transmigration used THP-1 cells for monocytes. THP-1 was introduced in the top channel and 
adhered to the PAEC. Transmigration effects were observed through the membrane as the 
monocytes travelled into the bottom channel. Stimulus effects were observed with the protein 
MCP-1, introduced solely in the bottom channel. Results from these trials showed that the 
introduction of MCP-1 lead to a roughly ten-fold increase in the number of transmigrated 
monocytes per square millimeter. Therefore, the effects of cell-cell interaction and stimuli 
replicated various scenarios in a microfluidic vasculature chip. The best conditions for in vitro 
monocyte adhesion are with TNF-α stimulation and fluid shear stress conditions, and the best 
conditions for transmigration are with MCP-1 stimulation. This shows how additional 
considerations within the device to mimic in vivo vasculature have the potential to produce the 
best results. 
 
2.7 Other Organs 
While the organs with the most prevalent research have been highlighted in previous sections, 
organ-on-a-chip systems have the potential to be used for many different organs. Researchers 
have been able to branch out in this respect and explore different ideas in unique systems tailored 
to their chosen organ.  Additionally, microfluidic organ-on-a-chip systems with cancerous organs 
will be explored, as well as multi-organ chips aimed to produce results working towards a body-
on-a-chip. 
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2.7.1 Bone marrow 
Torisawa et al. [67] designed a working bone marrow-on-a-chip device to replicate in vivo 
functions and study the effects of radiation-induced toxicity. The design features a PDMS 
cylindrical ring containing demineralized bone powder (DBP) and bone morphogenetic protein 2 
and 4 (BMP2, BMP4). A PDMS cap was placed over the top cavity of the ring to better regulate 
adipocytes for better hematopoiesis. Cultivation of these materials within the device was 
performed in vivo through implantation within a mouse. After 4-8 weeks, new bone structures 
were formed with a marrow inner region showing signs of cellular activity. The most prominent 
cells within the marrow were hematopoietic cells. Cultivation for 8 weeks within the mouse 
yielded the best results, with an array of cells that mimicked naturally grown bone marrow. Once 
the artificial bone marrow was removed from the rat, it was placed within a microfluidic PDMS 
chip (Fig. 10a-b). This chip contained PDMS layers containing microchannels designed above 
and below it. Two porous membrane layers were positioned between the layers containing 
microchannels and the culture chamber. The device showed it was capable of maintaining its 
structure and function for up a week with a medium containing cytokines. In comparison with 
naturally grown bone marrow extracted and cultured in a static system, the results from the 
microfluidic system showed similar functionality and viability of long-term hematopoietic stem 
cells (HSC). Freshly isolated bone marrow from both systems displayed the highest number of 
long-term HSC, with each subsequent day showing a decrease in that value.  Additionally, the 
naturally grown static trial also displayed a significant increase in progenitor cells after a period 
of time compared to freshly isolated bone marrow. Further trials exposed the microfluidic bone 
marrow device to γ-radiation to observe the toxic effects on the organs functionality and cell 
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viability. For control purposes, a system of the previously mentioned static culture with naturally 
grown bone marrow, as well as live mice, were tested as well. The various cell viabilities were 
tested at different radiation dosages. The results showed an inverse relationship between γ-
radiation dosage and cell viability for the HSC, progenitors, lymphoids, and myeloids. 
Granulocyte colony-stimulating factor (G-CSF), shown to inhibit radiation effects and promote 
recover of bone marrow in mice, was also tested in this fashion. Results showed that G-CSF did 
indeed provide a higher cell viability for bone marrow cells. Thus, the system was able to 
provide in vitro bone marrow functionality under normal conditions and toxic conditions that are 
comparable to in vivo results. Future toxicity tests with bone marrow diseases have the potential 
to be utilized using this technique. 
 
Fig. 10. A) Process of obtaining bone marrow cells highlighting the several key steps: implanting the 
device containing bone-inducing materials within the mouse, letting it cultivate within the mouse for 8 
weeks, and introducing the eBM (engineered bone marrow) into the chip. B) Images of this process can 
be seen, shown before implantation (left), after extraction from the mouse (middle), and the chip 
containing the eBM in its entirety. Scale bar is at 2mm [67]. 
b
a
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2.7.2 Brain 
Delivery of drugs and nutrients into the brain is regulated by the blood-brain barrier (BBB).  On 
the blood side of the barrier lies a complex array of vascular endothelial cells, and on the brain 
side lies the central nervous system. Issues maintaining functionality of the BBB can result in 
neurological disorders.  Thus, it is important to understand and test the effects that drugs might 
have on the BBB through in vitro design.  Therefore, with respect to the brain, most microfluidic 
models will feature a BBB-on-a-chip [68]. Griep et al. [69] designed a working BBB-on-a-chip and 
tested its functionality through TEER measurements. Two PDMS layers were constructed with a 
straight microfluidic channel that was positioned so that the top channel was perpendicular to the 
bottom channel. Additional grooves were created to fit in the electrodes for TEER measuring. A 
polycarbonate membrane was positioned between the two layers.  Human brain endothelial cells 
(hCMEC/D3) were cultivated in the top channel and showed a confluent monolayer within 1 
day. TEER results showed similar results between a static culture and the BBB chip, both 
displaying tight junctions and a confluent monolayer. Next, the effects of fluid shear stress on the 
hCMEC/D3 were tested.  After 3 days of normal function in the device, the BBB chip was 
exposed to shear stress of 5.8 dyn cm-2 for 18 hours. Results showed that the TEER value triple 
during the duration that shear stress was applied to the system. Afterwards, the effects of TNF-α 
stimulation was tested on the device. Directly following the 18 hours of exposure to fluid shear 
stress, 1 ng/ml of TNF-α was introduced to the system for 2 hours. Results showed that the 
TEER value dropped 10-fold when TNF-α was introduced. While this may show that the effects 
from TNF-α in the system make a much bigger impact than fluid shear stress, it is important to 
note that increasing TEER values is much more difficult to achieve than decreasing, since even 
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the slighted gap in the cell monolayer can significantly reduce TEER values [3a]. This experiment 
shows the capabilities of BBB models, with research already capable of considering the 
biochemical and mechanical factors that may contribute to its function. 
 
2.7.3 Spleen 
In the human body, the spleen serves the role of filtering blood, recycling red blood cells, and 
containing a reserve of white blood cells.  While a spleen can be removed from the body without 
suffering fatal injuries, it still serves important roles; of which an in vitro understanding can 
benefit, especially with an ultimate goal of creating a “body-on-a-chip.”  A “splenon-on-a-chip” 
design was created by Rigat-Brugarolas et al. [70].  This design mimics the red pulp area of the 
spleen by creating a fast-flow layer and a slow-flow layer.  The fluid going through the slow-
flow layer travels through a straight channel representing the 10% of blood that goes through a 
filtration process, where unhealthy red blood cells are destroyed.  This channel also contains an 
area filled with a pillar matrix, thereby impeding the flow and increasing the density in that area, 
representing a reticular mesh observed in an in vivo spleen. The fluid going through the fast-flow 
layer travels in a zig-zag pattern representing the rest of the blood going through the bypass of 
the filtration process. This device is connected to a syringe pump, providing flow at 5 µl min-1. 
Deformability studies can be performed on the device, with cells incapable of deforming 
showing constriction in the channels. Initial tests in the microfluidic system looked at the 
differences in deformability between new and aged red blood cells (RBC’s). Results showed that 
ages RBCs showed less deformability than new RBCs. The infected red blood cell (iRBC), 
Plasmodium yoelii-GFP, was then tested and compared to healthy RBCs. The results showed that 
healthy RBCs had a deformation measurement of roughly 19%, whereas the unhealthy iRBCs 
 
 
52 
had a deformation measurement of roughly 34%. This device shows a unique way of 
representing a 3D microfluidic spleen capable of identifying pathogens based on their 
deformability. 
 
2.7.4 Cancer/Tumor 
Modeling in vitro microfluidic chips to represent in vivo cancerous situations is a popular area of 
research.  Models involving lung [71], breast [72], prostate [73], pancreas [74], brain [75] cancer have 
been created. Song et al. [76] designed a microfluidic device to replicate the functionalities of 
breast cancer cells in a vasculature system.  The design consists of two PDMS layers containing 
microchannels, and a polyester membrane positioned between the layers.  The microchannel on 
the top layer contains a funnel-shaped inlet with a straight channel, while the bottom layer 
contains two straight channels located perpendicular to the top channel (Fig. 11A, D). Human 
dermal microvascular endothelial cells (HDMEC) are cultivated on the top of the membrane 
(Fig. 11C).  Trials consisted of introducing chemokines (CXCL12) contained in the medium 
through the lower channels, with breast cancer cells (MDA-MB-231) circulating through the top 
channel, with a focus on the adherence of the cancer cells on the endothelial cells in the 
overlapping channels (Fig. 11B, E, F). One of the contributing factors to cancer cell adhesion to 
the endothelial walls is the expressions of CXCR4 and CXCR7 receptors. Therefore, trials using 
cancer cells expressing CXCR4 (231-CXCR4) and CXCR7 (231-CXCR7) were also used to 
study their effects. Results showed that all three trials showed increased adhesion with faster 
flow rates. A significantly larger adhesive ability was also noted for trials containing CXCL12 in 
the HDMEC than trials without it. However, the ratio of treated cells to untreated cells showed 
similar values for all three. Therefore, while CXCL-12 enhances adhesion, it is independent of 
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CXCR4 and CXCR7.  To study the role HDMEC plays on adhesion, new trials were conducted 
in which the HDMEC monolayer was treated with CXCL12, which is known to up-regulate 
CXCR4, TNF-α, which is known to up-regulate both CXCR4 and CXCR7, and AMD3100 in 
combination with CXCL12, which inhibits binding for CXCL12-CXCR4, but not CXCL12-
CXCR7. These were tested in the downstream channel to observe the effects (Fig. 11G). Results 
showed that inhibiting the CXCL12-CXCR4 connection led to the lowest percentage of 
adhesion. This experiment showed not only a microfluidic device capable of replicating a 
microenvironment resembling breast cancer adhesion to the human vasculature, but also showed 
that disabling certain chemokine connections may prove to be an important step towards the 
regulation of metastasis. 
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Fig. 11. Design of the device, showing A) a layer-by-layer layout of the two PDMS layers with a 
membrane in-between them.  B) A cross-sectional view of the device can be seen at the location where the 
channels overlap, showing the flow of medium with cultured cells. C) HDMEC cultivation shown by 
region (upstream, middle, downstream) through phase contrast imaging (scale bar at 800μm).  D) An 
actual photo of the device, with a quarter for scale. E) Aerial view of the device, showing the locations of 
overlap, as well as the direction of flow. F) Interaction of HDMEC cells with flow from lower channel 
can be seen through fluorescent staining. Fluorescent dye was administered in the lower channels, 
showing interaction with the sections overlying the bottom channels, but not in the middle (scale bar at 
800μm). G) Adhesion of MDA-MD-231, with TNF-α treated only at the downstream channel (scale bar at 
200μm) [76]. 
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Cancer migration to bone is another scenario that has been researched. Bersini et al. [8] 
created a microfluidic system to look at the interaction between breast cancer cells within a 
microenvironment used to represent bone structure. The device uses 3 microchannels with 8 
hydrogel regions within 4 hydrogel channels. Culture media flows through the 3 microchannels, 
with HUVEC cells cultivated in the central channel. Cultivated hBM-MSC bone marrow cells 
within a collagen type 1 solution were injected into the 4 hydrogel channels structured with 
ECM. This produced an osteo-cell region within the hydrogel channel. After 3 days of 
cultivation, breast cancer cells (MDA-MB-231) were introduced to the system. Trials focused on 
observing the cross-talk between the osteo-cell regions and the breast cancer cells. Specifically, 
the interactions of CXCL5, a chemokine derived from the hBM-MSC, and the CXCR2 receptor 
from MDA-MB-231.  Results showed that in comparison to a gel only region (38%), the osteo-
cell hydrogel region contained more transmigrated cancer cells (78%). These cancer cells were 
also able to penetrate deeper into the osteo-cell microenvironment. Additionally, the 
transmigrated cells showed signs of proliferation within the osteo-cell region. These proliferated 
cancer cells formed in clumps ranging from 4-60 cells. These results were successful in showing 
a functional cancer-bone cross-talk environment. Additionally, their environment promoted 
cancer cell transmigration, both in quantity and depth. Taking this into account, along with the 
observations of cancer cell metastasis within the osteo-cell region after transmigration, it is clear 
that the osteo-cell region provided a suitable environment for cancer cells. 
A design focused on the extravasation of cancer cells through an endothelial barrier was 
developed by Jeon et al. [77]. Similar to the previous design, this design contained three 
microfluidic channels with hydrogel compartments separating each channel.  These hydrogel 
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compartments contained an ECM structure. Human microvascular endothelial cells (hMVECs) 
were seeded within the central channel and cultured in the device. The cell line MDA-MB-231 
was used to represent the tumor cells. These cells were also introduced into the central challenge 
after a confluent monolayer of hMVEC cells were formed. Results showed a successful 
extravasation of tumor cells through the endothelial barrier, with signs of proliferation in the 
ECM gel. Additionally, it was found that the number of extravasated cells stagnated after the 
first day, in agreement with in vivo studies. 
 
2.7.5 Multiple Organs 
As briefly discussed earlier in this paper, organ-on-a-chip technology can be applied to a 
system of multiple organs, and sometimes dubbed “human-on-a-chip,” depending on how large 
of a portion of the human body the device represents.  This has been the focal point to some 
research topics [78].  Multiple organs-on-a-chip provide their own challenges mainly due to their 
complexity.  Organ-organ interactions themselves add another layer of complexity to the system 
[79]. 
Scaling from a multiple organ-on-a-chip in order to apply to in vivo humans is a 
challenge in and of itself [80].  Before body-on-a-chip systems can be implemented, consideration 
of the scaling effect between these micro-representations of organs with their actual in vivo 
counterparts must be done. Wikswo et al. [80a] broke this idea down into several groups.  
First, an allometric scaling can be done to represent organs. Because humans scale 
allometrically, scaling differences between interconnected organ-on-a-chip systems provide an 
especially difficult challenge for researchers. Not only would scaling involve considerations for 
the mass allometrics of the organs, but properties such as blood circulation and pulse would also 
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be affected by scaling. Another consideration would be the aspects and properties of organs that 
are independent of size, which may fail or become dysfunctional when scaled. 
The second approach towards dealing with scaling is considering the human-on-a-chip as 
only a portion of the human body, dubbed “histological sections”. In this respect, scaling 
considerations become unnecessary. The design can be such that the designed section of the 
organ only needs to perform the physiological duties associated with that section, eliminating 
some of the complexity of mimicking in vivo organs. Issues can arise when combining these 
sections due to either misrepresenting the organ-organ interactions by not considering the effects 
of a missing section of one of the organs or by not accounting for the scales of the sections 
relative to each other. 
The third approach is to scale with consideration to organ functions. In other words, the 
preservation of the important organ functions is paramount when scaling in this respect. The 
drawback for this approach is that it may oversimplify the design to the point where various 
results aren’t translatable. 
Work done by Zhang et al. [81], combined a multi-channel three dimensional cell culture 
system with compartments for different cells. Four different organs were tested in this system: 
C3A cells (liver), A549 cells (lung), HK-2 cells (kidney) and HPA cells (fat). All organs were 
connected and a “common medium” (CM) was created to keep the functions of each individual 
cell line. Results showed that all but the HK-2 cells were able to function at expected levels, with 
HK-2 functionality decreased 10%. Despite this shortcoming, the medium was deemed suitable 
for the experiment.  The cells were connected to a reservoir containing the medium, with 
connections to an inlet directly attached to each cell group. The effects of TGF-β1 were tested in 
the multi-chip. Results showed that it did have the capabilities of promoting cell growth in A549, 
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HK-2, and HPA cells. However, it also resulted in a much lower viability of C3A cells. To 
counteract this effect, gelatin microspheres were fabricated, with the ability to control the release 
of TGF-β1 so that it is only delivered in the A549 cell group. The results showed that A549 cells 
were indeed stimulated without adverse effects to any other cells. This experiment is capable of 
testing the multi-organ implications from drug toxicity testing. 
A microscale cell culture analog (µCCA) based on a pharmacokinetic-pharmacodynamic 
(PK-PD) mathematical model has also been explored as a means to create a “body-on-a-chip” 
[82].  This model has the potential to be able to mathematically predict and map out the 
pharmacological effects of a drug. Sung et al. [83] tested the capabilities of PK-PD modeling with 
a multi-organ chip device designed to test drug toxicity. Three different cell lines were cultivated 
in separate cell culture chambers: HepG2/C3A (liver), HCT-116 (tumor), and Kasumi-1 
(marrow). A reservoir containing suitable medium is fed into the three cell culture chambers. 
Flow was induced through a rocking motion, allowing gravity to control the flow rate. This 
devices changes course every 3 minutes, ensuring that good viability is maintained throughout 
the device. Layout of the device can be seen in Fig. 12. Trials were done in which 5-fluorouracil 
(5-FU), an anti-cancer drug, was introduced into the medium. Different trials were done at 
varying concentrations. Both PK-PD modeling and experimental testing were done to observe 
the results.  Results from experimental data show similar trends. Further trials were conducted 
using both 5-FU and uracil, which is known as a modulator of 5-FU. Results showed a decline in 
viability between all three cell groups. Through this experiment, PK-PD modeling and 
microfluidic multi-organ functionality were combined to test the functionality when introduced 
to a drug test. The results obtained from this experiment are promising, and may lead to future 
studies in this area.  
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Fig. 12. Layout of the device, showing A) the layer-by-layer design, and B) the image of the assembled 
device, with a quarter for scale [83]. 
A sample design of a body-on-a-chip was designed using chips discussed in this paper 
(Fig. 13.). When inter-connecting organ-on-a-chips, it is vital to recognize which organs must 
interact with others, and conversely, which organs must be separated from others. The medium 
introduced must be able to interact with the various cells without harming them. 
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Fig. 13. Sample construction of a body-on-a-chip using microfluidic chips discussed in this paper.  Drug 
testing would begin at the lung [26] or gut [40], with the liver [16] only accessible through the gut. From 
there, the flow would travel in the blood, reaching the kidney [50], heart [58], bone marrow [67], brain [69], 
spleen [70], and vasculature [66].  
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3. Summary Table 
The table categorizes each work based on the type of organ, type of testing, details of the design 
and experiments, and the cells used. 
 
Organ Type of 
testing 
Details Cultured cells in device Author 
          
Liver Toxicity/ 
Drug 
Testing 
Created 3D HepaTox Chip for 
hepatotoxicity testing 
Harvested rat 
hepatocytes 
Toh et al. 
[13] 
    Encapsulated hepatocytes in 3D 
microtissues to study the interactions of 
drugs 
Harvested rat 
hepatocytes 
Li et al. [12a] 
    MODS platform for hepatotoxicity 
screening 
HepG2 and NIH-3T3 Au et al. 
[17b] 
    Characterizing the toxicity of several 
compounds using liver co-culture and 
SMART-scale analysis 
HepG2/C3A and MDCK Shintu et 
al. [20] 
    Drug metabolism using liver and intestinal 
slices 
Harvested rat liver and 
intestinal slices 
van 
Midwoud 
[22] 
    Testing the effects of ethanol-induced 
toxicity on liver slices 
Harvested rat liver 
slices 
Hattersley 
et al. [21] 
  Function
al 
analysis 
Creating model with bile canaliculi 
formation 
Harvested rat 
hepatocytes 
Nakao et 
al. [14] 
    Incorperated biosensors for pH monitoring 
in chip  
HepG2 Schober et 
al. [15] 
    The kinetic reactions representing 
metabolism, measured and compared with 
mathematical model  
Harvested rat liver 
microsomes 
Lee et al. 
[16] 
    Liver sinusoid pattern assembly through 
use of dielectrophoresis 
Primary human 
hepatocytes and 
endothelial cells 
Schütte et 
al. [18] 
    Mimicking of the acinus function in the 
liver 
Hepatocytes and 
nonparenchymal cells 
Bhushan et 
al. [17a] 
    Liver and skin co-culture used to test long-
term functionality under 
HHSteC and skin 
biopsies 
Wagner et 
al. [19] 
    Created IIDMP to evaluate dynamic organ-
organ interactions of the liver and 
intestine 
HepG2/C3A and Caco-2 
TC7 
Bricks et al. 
[23] 
 
 
62 
Lung Toxicity/ 
Drug 
Testing 
Modeling disease functions through a chip 
undergoing cyclic mechanical strain 
Human alveolar 
epithelial/microvascular 
endothelial cells 
Huh et al. 
[27] 
    Cellular response and resistance to 
anticancer drug testing 
SK-MES-1 Siyan et al. 
[32] 
    Modeling the nasal epithelium for 
formaldehyde toxicity testing 
NIH/3T3 and hNESPC Wang et al. 
[34] 
  Function
al 
analysis 
Representing pulmonary diseases through 
propogating liquid plugs 
SAEC Huh et al. 
[25] 
    Analysis of the role of surfactants in liquid 
plug injury 
A549, ATCC Tavana et 
al. [26] 
    Testing the transport properties with 
physiological "breathing" chip design 
Human alveolar 
epithelial/microvascular 
endothelial cells 
Huh et al. 
[7] 
    Observing cellular injury through both 
solid and fluid mechanical stress 
A549, AEC Douville et 
al. [28] 
    Producing suitable levels of gas transfer 
for artificial lung applications 
N/A Kniazeva et 
al. [29] 
    Gaseous exchange in vascular network 
through creation of free-standing 
membranes 
N/A Sreenivasa
n et al. [31] 
    Optimizing flow and gaseous exchange 
through use of a vascular scaffold 
N/A Hoganson 
et al. [30] 
Intesti
ne 
Toxicity/ 
Drug 
Testing 
μCCA model to study GI tract and predict 
drug toxicity 
Caco-2 and HepG2/C3A Mahler et 
al. [36] 
    Testing drug permeability in the intestinal 
epithelial cell membrane through use of 
microhole trapping 
Caco-2 Yeon et al. 
[44] 
  Function
al 
analysis 
Use of hydrogels as a platform for 
cultivated cells in a GI tract design 
Caco-2 Sung et al. 
[38] 
    Functional model for potential integration 
in a body-on-a-chip design 
Caco-2 Esch et al. 
[37a] 
    Compound analysis through pH control 
with respect to GI tract activity 
N/A Morimoto 
et al. [37b] 
    Mimicking the function of mucus secretion 
in the stomach 
N/A Li et al. [37c] 
    Characteristing flow and transport 
properties of the instines using a villi 
scaffold 
Caco-2 Kim et al. 
[37d] 
    Modeling lipid digestion in various 
gastrointestinal conditions 
N/A Marze et 
al. [37e] 
    Analyzing signals through bacteria-cell 
interaction in GI tract 
HeLa S3 Kim et al. 
[39] 
    Utilizing mechanical stress and microbes in Caco-2 Kim et al. 
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a gut-on-a-chip [40] 
    Generation of 3D intestinal villi through 
introduction of mechanical stress 
Caco-2 Kim et al. 
[41] 
    Use of polarized cells to create 
microenvironment suited for long-term 
perfusion 
Caco-2 Kimura et 
al. [42] 
    Testing the permeation abilities and 
intestinal absorption through microfluidics 
Caco-2 Imura et al. 
[43] 
Kidney Toxicity/ 
Drug 
Testing 
Testing the effects of drugs on the 
profliferation of a dynamic kidney 
microfluidic chip  
MDCK Baudoin et 
al. [47] 
    Exposure to fluid flow to create 
functionality and measure nephrotoxicity 
activity 
Human kidney proximal 
tubular epithelial cells 
Jang et al. 
[50] 
  Function
al 
analysis 
Using optical vortices to enhance the 
functions of a blood cleaner-on-a-chip 
N/A Suwanpaya
k et al. [46a] 
    Fabricating a nanofiber membrane for 
filtration in a microfluidic design 
N/A Lee et al. 
[46b] 
    Analyzing the gene and protein expression 
in MDCK cells 
MDCK Snouber et 
al. [46c] 
    Role of patterned membrane in renal chip 
function 
HK-2 and RPTEC Frohlich et 
al. [46d] 
    Use of adipose-derived stem cells in 
enhacing renal properties and functions 
MDCK and CG-ASC Huang et 
al. [46e] 
    Utilization of fluid shear stress to enhance 
renal functions 
IMCD Jang et al. 
[48] 
    Collecting duct-on-a-chip to investigate 
the effects of changes within a renal 
environment 
IMCD Jang et al. 
[49] 
    MTMD capable of utilizing fluid shear 
stress and topographical patterns 
HK-2 Frohlich et 
al. [51] 
    Using TEER measurements to analyze a 
working kidney bioreactor under fluid 
shear stress conditions 
HREC and MDCK Ferrell et 
al. [52] 
    Analyzing filtration for mass transfer 
capabilities modeling a glomerular unit 
N/A Ould-Dris 
et al. [53] 
    Investigation of the properties of mass 
transfer and drug transport in MDCK cells 
MDCK Ramello et 
al. [54] 
Heart Function
al 
analysis 
Studying the contraction of a single 
cardiomyocyte 
Harvested rabbit heart 
tissue 
Li et al. [57a] 
    Measurements conducted through 
electrode array analyzing a functioning 
cardiomyocyte 
Harvested rabbit 
ventricular myocytes 
Cheng et 
al. [57b] 
    Effects of myocardial injury in a micropillar 
array environment 
H9C2 Ren et al. 
[57c] 
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    Reconstituting Barth's syndrome through a 
functional heart-on-a-chip 
iPSC-CM Wang et al. 
[57d] 
    Studying the functions of skeletal 
myoblasts for myocardial injury 
H9C2 and L6 myoblasts He et al. 
[57e] 
    Replicating physical loading in the left 
ventricle through a μCCCM 
H9C2 Giridharan 
et al. [58] 
    Fabrication of micro spherical pump made 
from cardiomyocytes 
Rat cardiomyocyte cells Tanaka et 
al. [60] 
    TSM sensor for acoustic wave analysis of 
cardiomyocyte contractions 
Rat ventricular 
cardiomyocytes 
Li et al. [61] 
    SVF method for organ tissue analysis Chick heart Owaki et 
al. [62] 
Vascul
ature 
Function
al 
analysis 
Implantable microfluidic device for 
formation of vasculature 
hEPC Kim et al. 
[64a] 
    Studying the effects of the architecture in 
the vasculature through ECM distribution 
HUVEC Baker et al. 
[64b] 
    Creation of vasculature network through 
material fracture 
N/A Huang et 
al. [64c] 
    Establishing vasculature transport for use 
in multi-organ applciations 
HDMEC Schimek et 
al. [64d] 
    Creating diffusive vasculature network 
from hydrogel 
pHUVEC Mu et al. 
[64e] 
    Using TEMS to replicate vasculature 
environment 
HUVEC, hCMEC/D3, BT-
474/PC3 
Tourovskai
a et al. [64f] 
    Bifurcating microchannel vasculature 
network with circular cross-sections 
HUVEC Borenstein 
et al. [65] 
    Effects of shear stress, monocyte-EC 
adhesion, and monocyte transmigration 
on a vasculature system 
PAEC, RAW264.7, THP-1 Srigunapala
n et al. [66] 
Bone 
Marro
w 
Toxicity/ 
Drug 
Testing 
Radiation-induced toxicity effects on a 
bone marrow-on-a-chip 
hematopoietic and 
adipocyte cells 
Torisawa et 
al. [67] 
Cance
r/Tum
or 
Toxicity/ 
Drug 
Testing 
Studying chemotherapy resistance using a 
lung cancer microfluidic model 
SPCA1 Zhang et al. 
[71a] 
    Effects of anticancer drugs on lung and 
stromal cells 
SPCA1 and HFL1 Xu et al. 
[71b] 
    Analysis of CTCs in multiple lung cancer 
cell lines 
A459, SK-MES-1, and 
H446 
Huang et 
al. [71c] 
    Analysis of chemotherapy resistance and 
inhibitors for lung cancer model 
SPCA1 Meng et al. 
[71d] 
    Observing the effects of various drugs on 
breast cancer cells through a droplet 
microfluidic device 
MDC-MB-231 Gong et al. 
[72d] 
  Function
al 
MMICH platform for diagnosis of breast 
cancer  
AU-565, SK-BR-3, 
HCC70, and MCF-7 
Kim et al. 
[72a] 
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analysis 
    Detection of breast cancer recurrence 
using PDMAEMA 
N/A Chen et al. 
[72b] 
    Modeling the transition from DCIS to IDC 
for breast cancer analysis 
MCF-DCIS and HMF Sung et al. 
[72c] 
    CTC capture and analysis for prostate 
cancer in a GEDI device 
U937, PC-3, LNCaP, and 
C4-2 
Kirby et al. 
[73a] 
    EIS biosensor for prostate cancer 
screening 
N/A Chiriacò et 
al [73b] 
    Separation of prostate cancer cells from 
white blood cells using acoustophoresis 
DU145, PC3, LNCaP Augustsson 
et al. [73c] 
    Recreating prostate cancer 
microenvironment using fluid shear stress 
PC-3 Liu et al. 
[73d] 
    Analysis of CTC in pancreatic cancer cell 
line 
MCF-7, Hs578T, and 
SW620 
Kamande 
et al. [74] 
    Using an MCS for characterization of brain 
cancer cells 
A172, 1321N1, L0329, 
and L0367 
Khan et al. 
[75] 
    Replicating the functionalities of breast 
cancer cells ina vasculature system 
HDMEC and MDA-MB-
231 
Song et al. 
[76] 
    Observing the effects of breast cancer cells 
within a bone structure microenvironment 
HUVEC, hBM-MSC, and 
MDA-MB-231 
Bersini et 
al. [8] 
    Extravasation of cancer cells through an 
endothelial barrier 
hMVEC and MDA-MB-
231 
Jeon et al. 
[77] 
Brain Toxicity/ 
Drug 
Testing 
Drug permeability testing through the BBB HUVEC Yeon et al. 
[68c] 
  Function
al 
analysis 
Creation and utilization of a SyM-BBB to 
monitor tight junctions and permeability 
RBE4 Prabhakarp
andian et 
al. [68a] 
    Analysis of μBBB device to replicate 
permeability and cell characteristics 
b.END3 and C8D1A Booth et al. 
[68b] 
    Integrating collagen into BBB model 
capable of permeability and shear stress 
analysis 
Endothelial cell, 
pericyte, and astroglia 
Shibata et 
al. [68d] 
    Use of TEER measurements to test 
functionality of BBB-on-a-chip 
hCMEC/D3 Griep et al. 
[69] 
Spleen Function
al 
analysis 
Fast-flow/Slow-flow device for testing 
deformability of RBC in the spleen model 
N/A Rigat-
Brugarolas 
et al. [70] 
Multip
le 
Organ
s 
Toxicity/ 
Drug 
Testing 
Multi-cell design for monitoring glucose 
concentration in the presense of various 
metabolites 
Omental adipose tissue, 
HUVEC, and HepG2 
Iori et al. 
[78b] 
    Monitoring the multi-organ implications 
from drug toxicity testing 
C3A, A549, HK-2, and 
HPA 
Zhang et al. 
[81] 
    Testing toxicity effects on multi-cell device 
complete with a hydrogel structural 
HCT-116, GepG2/C3A, 
and Kasumi-1 
Sung et al. 
[82b] 
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microenvironment 
    µCCA based on PK-PD model to predict 
pharmacological effects of a drug 
HCT-116, GepG2/C3A, 
and Kasumi-1 
Sung et al. 
[83] 
  Function
al 
analysis 
Hanging drop technique for fabrication of 
multi-cell device 
HCT-116 eGFP and 
rLiMT 
Frey et al. 
[78a] 
 
4. Conclusions 
Organ-on-a-chip systems are still a relatively new area of research, but have shown the potential 
to produce successful results with few caveats.  For this reason, it is important to be able to 
expand the horizon with these systems and explore new ideas within this area. In a broader sense, 
this research promotes the exploration of cheap, reliable alternatives to other forms of drug 
testing.  Organ-on-a-chip designs have the potential to be mass produced and use few amounts of 
materials.  This would have the potential of being used universally, including underdeveloped 
countries.  
However, there are still steps needed to be taken in order to reach this level of reliability. 
While most tests have shown the ability to mimic organ functions and reactions, these are still 
not at the level to be a successful alternative to in vivo studies. Issues with inducing all the 
potential mechanical forces, achieving respectable permeation rates, producing efficient flow 
through polymer compartments, and recreating the microscale ecosystem of organisms, cells, 
bacteria that are relevant to the function of the organs, are considerations that require continued 
improvement. Additionally, single organ studies neglect to consider the implications that other 
organs within the same flow would have on that organ. Body-on-a-chip studies show great 
promise in this respect, but issues with components positively effecting one culture and 
negatively affecting another must be corrected. Methods like creating a gelatin microsphere for 
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time-release drugs or providing a common medium to the system have shown promise as a way 
to integrate multiple cell cultures. 
Through this review, individual organs are analyzed, with attention brought to their 
design, materials, objectives, and results. Additionally, multi-organ systems are discussed, with a 
sample model of a “body-on-a-chip” created using designs mentioned in this paper. While it may 
not be as straightforward as simply connecting the designs with one another, this construction of 
a body-on-a-chip shows that the ability to create a successful body-on-a-chip is not 
inconceivable with successful designs of individual organs. 
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